Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:dopamine
go back to main search page
Accession:CHEBI:18243 term browser browse the term
Definition:Catechol in which the hydrogen at position 4 is substituted by a 2-aminoethyl group.
Synonyms:related_synonym: 2-(3,4-Dihydroxyphenyl)ethylamine;   3,4-Dihydroxyphenethylamine;   3-Hydroxytyramine;   4-(2-Aminoethyl)-1,2-benzenediol;   4-(2-Aminoethyl)benzene-1,2-diol;   4-(2-aminoethyl)catechol;   4-(2-aminoethyl)pyrocatechol;   Deoxyepinephrine;   Formula=C8H11NO2;   Hydroxytyramin;   InChI=1S/C8H11NO2/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,5,10-11H,3-4,9H2;   InChIKey=VYFYYTLLBUKUHU-UHFFFAOYSA-N;   SMILES=NCCc1ccc(O)c(O)c1;   dopamina;   dopaminum
 alt_id: CHEBI:11695;   CHEBI:11930;   CHEBI:14203;   CHEBI:1764;   CHEBI:23886;   CHEBI:43686
 xref: CAS:51-61-6;   DrugBank:DB00988;   Drug_Central:947;   HMDB:HMDB0000073;   KEGG:C03758;   KEGG:D07870;   KNApSAcK:C00001408;   LINCS:LSM-4630
 xref_mesh: MESH:D004298
 xref: MetaCyc:DOPAMINE;   PMID:10629745;   PMID:11149432;   PMID:9422813;   Reaxys:1072822;   Wikipedia:Dopamine
 cyclic_relationship: is_conjugate_base_of CHEBI:59905


show annotations for term's descendants           Sort by:
dopamine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G A3galt2 alpha 1,3-galactosyltransferase 2 increases expression EXP Dopamine results in increased expression of A3GALT2 mRNA CTD PMID:21983523 NCBI chr 5:141,101,329...141,113,760
Ensembl chr 5:141,107,983...141,115,641 		JBrowse link
G Abl2 ABL proto-oncogene 2, non-receptor tyrosine kinase decreases expression EXP Dopamine results in decreased expression of ABL2 mRNA CTD PMID:21983523 NCBI chr13:68,673,702...68,770,846
Ensembl chr13:68,673,722...68,839,742 		JBrowse link
G Actb actin, beta affects expression ISO Dopamine affects the expression of ACTB protein CTD PMID:24675778 NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877 		JBrowse link
G Actbl2 actin, beta-like 2 decreases expression ISO Dopamine results in decreased expression of ACTBL2 protein CTD PMID:24675778 NCBI chr 2:42,858,020...42,860,767
Ensembl chr 2:42,858,020...42,860,767 		JBrowse link
G Actg1 actin, gamma 1 increases expression EXP Dopamine results in increased expression of ACTG1 mRNA CTD PMID:21983523 NCBI chr10:105,619,738...105,622,587
Ensembl chr10:105,619,737...105,624,232
Ensembl chr 3:105,619,737...105,624,232 		JBrowse link
G Adam9 ADAM metallopeptidase domain 9 increases expression EXP Dopamine results in increased expression of ADAM9 mRNA CTD PMID:21983523 NCBI chr16:67,022,538...67,101,647
Ensembl chr16:67,022,655...67,100,917 		JBrowse link
G Adamts4 ADAM metallopeptidase with thrombospondin type 1 motif, 4 increases expression EXP Dopamine results in increased expression of ADAMTS4 mRNA CTD PMID:21983523 NCBI chr13:83,670,556...83,680,045
Ensembl chr13:83,670,183...83,680,065 		JBrowse link
G Adora1 adenosine A1 receptor multiple interactions EXP [N(6)-cyclohexyladenosine binds to and results in increased activity of ADORA1 protein] promotes the reaction [Methamphetamine results in increased secretion of Dopamine] CTD PMID:11043458 NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801 		JBrowse link
G Adra2a adrenoceptor alpha 2A affects binding ISO Dopamine binds to ADRA2A protein CTD PMID:10336518 NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365 		JBrowse link
G Adra2c adrenoceptor alpha 2C affects binding ISO Dopamine binds to ADRA2C protein CTD PMID:10336518 NCBI chr14:75,470,884...75,472,846
Ensembl chr14:75,471,143...75,472,846 		JBrowse link
G Adrb2 adrenoceptor beta 2 multiple interactions EXP [Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Dopamine; ICI 118551 inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Dopamine] CTD PMID:10894789 NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512 		JBrowse link
G Agt angiotensinogen multiple interactions ISO Clozapine inhibits the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]]; Clozapine promotes the reaction [Raclopride promotes the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]]]; Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]; Raclopride inhibits the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]]; Raclopride promotes the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]] CTD PMID:11549694 NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977 		JBrowse link
G Aldh2 aldehyde dehydrogenase 2 family member multiple interactions EXP [[CVT-10216 results in decreased activity of ALDH2 protein] which results in increased abundance of Tetrahydropapaveroline] inhibits the reaction [Cocaine results in increased abundance of and results in increased secretion of Dopamine]; ALDH2 protein affects the reaction [Cocaine results in increased abundance of Dopamine] CTD PMID:20729865 NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521 		JBrowse link
G Aldoa aldolase, fructose-bisphosphate A increases expression ISO Dopamine results in increased expression of ALDOA protein CTD PMID:24675778 NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182 		JBrowse link
G Anxa3 annexin A3 increases expression ISO Dopamine results in increased expression of ANXA3 protein CTD PMID:24675778 NCBI chr14:12,727,708...12,781,717
Ensembl chr14:12,719,795...12,781,617 		JBrowse link
G Arg1 arginase 1 decreases expression EXP Dopamine results in decreased expression of ARG1 mRNA; Dopamine results in decreased expression of ARG1 protein CTD PMID:25818600 NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422 		JBrowse link
G Arrb1 arrestin, beta 1 multiple interactions ISO Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB1 protein]; GRK2 protein promotes the reaction [Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB1 protein]] CTD PMID:31024316 NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061 		JBrowse link
G Arrb2 arrestin, beta 2 multiple interactions ISO Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB2 protein]] CTD PMID:31024316 NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850 		JBrowse link
G Atp2b2 ATPase plasma membrane Ca2+ transporting 2 decreases expression EXP Dopamine results in decreased expression of ATP2B2 mRNA CTD PMID:21983523 NCBI chr 4:146,894,602...147,208,060
Ensembl chr 4:146,896,332...147,140,665 		JBrowse link
G Atp5pd ATP synthase peripheral stalk subunit d increases expression ISO Dopamine results in increased expression of ATP5PD protein CTD PMID:24675778 NCBI chr10:100,657,700...100,662,960
Ensembl chr10:100,657,708...100,663,479 		JBrowse link
G B4galt1 beta-1,4-galactosyltransferase 1 increases expression EXP Dopamine results in increased expression of B4GALT1 mRNA CTD PMID:21983523 NCBI chr 5:55,935,614...55,982,461
Ensembl chr 5:55,935,615...55,982,461 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator decreases expression ISO Dopamine results in decreased expression of BAX protein CTD PMID:19410601 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bbc3 Bcl-2 binding component 3 increases expression ISO [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BBC3 mRNA; [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BBC3 protein CTD PMID:19410601 NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509 		JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression
multiple interactions		 ISO Dopamine results in decreased expression of BCL2 protein
polydatin inhibits the reaction [Dopamine results in decreased expression of BCL2 protein]; Resveratrol inhibits the reaction [Dopamine results in decreased expression of BCL2 protein]		 CTD PMID:17603292 PMID:28980048 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Bdnf brain-derived neurotrophic factor increases abundance ISO BDNF gene mutant form results in increased abundance of Dopamine CTD PMID:11421589 NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615 		JBrowse link
G Bnip3 BCL2 interacting protein 3 increases expression ISO [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BNIP3 mRNA; [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BNIP3 protein CTD PMID:19410601 NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359 		JBrowse link
G C1qbp complement C1q binding protein increases expression ISO Dopamine results in increased expression of C1QBP protein CTD PMID:24675778 NCBI chr10:55,699,954...55,704,605
Ensembl chr10:55,699,954...55,704,649 		JBrowse link
G Calu calumenin increases expression EXP Dopamine results in increased expression of CALU mRNA CTD PMID:21983523 NCBI chr 4:57,949,086...57,976,589
Ensembl chr 4:57,948,997...57,976,593 		JBrowse link
G Caly calcyon neuron-specific vesicular protein decreases secretion ISO CALY protein results in decreased secretion of Dopamine CTD PMID:30753204 NCBI chr 1:194,862,671...194,873,861
Ensembl chr 1:194,862,672...194,873,551 		JBrowse link
G Camk2a calcium/calmodulin-dependent protein kinase II alpha multiple interactions EXP [Ionomycin co-treated with CAMK2A protein] inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]] CTD PMID:19217379 NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994 		JBrowse link
G Casp3 caspase 3 multiple interactions
increases activity
increases cleavage		 ISO
EXP		 [Dopamine co-treated with Zinc deficiency] results in increased activity of CASP3 protein; Acetylcysteine inhibits the reaction [Dopamine results in increased activity of and results in increased cleavage of CASP3 protein]; Dopamine results in increased activity of and results in increased cleavage of CASP3 protein; Dopamine results in increased cleavage of and results in increased activity of CASP3 protein; PRKN protein inhibits the reaction [Dopamine results in increased cleavage of CASP3 protein]; resveratrol inhibits the reaction [Dopamine results in increased cleavage of and results in increased activity of CASP3 protein]
Dopamine results in increased activity of CASP3 protein
SH-6 compound promotes the reaction [Dopamine results in increased activity of CASP3 protein]; SH-6 compound promotes the reaction [tanespimycin promotes the reaction [Dopamine results in increased activity of CASP3 protein]]; tanespimycin promotes the reaction [Dopamine results in increased activity of CASP3 protein]		 CTD PMID:15198987 PMID:17136323 PMID:17603292 PMID:18194434 PMID:19410601 More... NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp7 caspase 7 multiple interactions
increases activity		 ISO Acetylcysteine inhibits the reaction [Dopamine results in increased activity of and results in increased cleavage of CASP7 protein]; Dopamine results in increased activity of and results in increased cleavage of CASP7 protein
Dopamine results in increased activity of CASP7 protein		 CTD PMID:17136323 PMID:19410601 NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729 		JBrowse link
G Cat catalase multiple interactions
increases expression		 ISO
EXP		 CAT protein inhibits the reaction [N-Methyl-3,4-methylenedioxyamphetamine results in decreased abundance of Dopamine]
Dopamine results in increased expression of CAT mRNA
[Dopamine co-treated with Dicumarol] results in increased expression of CAT mRNA		 CTD PMID:11299314 PMID:11435997 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478 		JBrowse link
G Cbx7 chromobox 7 decreases expression EXP Dopamine results in decreased expression of CBX7 mRNA CTD PMID:21983523 NCBI chr 7:111,460,656...111,479,231
Ensembl chr 7:111,460,656...111,477,973 		JBrowse link
G Ccl22 C-C motif chemokine ligand 22 decreases expression EXP Dopamine results in decreased expression of CCL22 mRNA CTD PMID:25818600 NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400 		JBrowse link
G Cd55 CD55 molecule (Cromer blood group) increases expression EXP Dopamine results in increased expression of CD55 mRNA CTD PMID:21983523 NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831 		JBrowse link
G Cfl1 cofilin 1 increases expression ISO Dopamine results in increased expression of CFL1 protein CTD PMID:24675778 NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587 		JBrowse link
G Chrm5 cholinergic receptor, muscarinic 5 decreases secretion
affects secretion		 ISO CHRM5 gene mutant form results in decreased secretion of Dopamine
CHRM5 protein affects the secretion of Dopamine		 CTD PMID:15213703 NCBI chr 3:99,284,846...99,337,252
Ensembl chr 3:99,284,846...99,337,252 		JBrowse link
G Chrna3 cholinergic receptor nicotinic alpha 3 subunit increases secretion EXP CHRNA3 protein results in increased secretion of Dopamine CTD PMID:15542623 NCBI chr 8:55,401,668...55,415,165
Ensembl chr 8:55,401,702...55,415,165 		JBrowse link
G Chrna4 cholinergic receptor nicotinic alpha 4 subunit affects binding EXP dopamine binds to Chrna4 protein in rat brain striatal sections RGD PMID:22550286 RGD:8549526 NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957 		JBrowse link
G Chrna6 cholinergic receptor nicotinic alpha 6 subunit multiple interactions ISO [pozanicline binds to and results in increased activity of [CHRNA6 protein binds to CHRNB2 protein]] which results in increased secretion of Dopamine; Nicotine inhibits the reaction [[CHRNA6 protein binds to CHRNB2 protein] which results in increased secretion of Dopamine] CTD PMID:17227438 PMID:19481067 NCBI chr16:64,697,741...64,704,441
Ensembl chr16:64,697,741...64,704,441 		JBrowse link
G Chrnb2 cholinergic receptor nicotinic beta 2 subunit multiple interactions ISO [pozanicline binds to and results in increased activity of [CHRNA6 protein binds to CHRNB2 protein]] which results in increased secretion of Dopamine; Nicotine inhibits the reaction [[CHRNA6 protein binds to CHRNB2 protein] which results in increased secretion of Dopamine] CTD PMID:17227438 PMID:19481067 NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619 		JBrowse link
G Chrnb4 cholinergic receptor nicotinic beta 4 subunit increases secretion EXP CHRNB4 protein results in increased secretion of Dopamine CTD PMID:15542623 NCBI chr 8:55,417,583...55,437,027
Ensembl chr 8:55,418,313...55,437,027 		JBrowse link
G Ckap4 cytoskeleton-associated protein 4 increases expression EXP Dopamine results in increased expression of CKAP4 mRNA CTD PMID:21983523 NCBI chr 7:19,230,814...19,238,914
Ensembl chr 7:19,230,203...19,238,914 		JBrowse link
G Clic1 chloride intracellular channel 1 increases expression EXP Dopamine results in increased expression of CLIC1 mRNA CTD PMID:21983523 NCBI chr20:3,764,867...3,773,711
Ensembl chr20:3,761,461...3,773,712 		JBrowse link
G Col12a1 collagen type XII alpha 1 chain increases expression EXP Dopamine results in increased expression of COL12A1 mRNA CTD PMID:21983523 NCBI chr 8:80,547,592...80,665,665
Ensembl chr 8:80,547,593...80,665,686 		JBrowse link
G Comt catechol-O-methyltransferase increases methylation
increases metabolic processing
multiple interactions		 ISO
EXP		 COMT protein results in increased methylation of Dopamine
COMT protein results in increased metabolism of Dopamine
[tolcapone results in decreased activity of COMT protein] promotes the reaction [Clozapine results in increased abundance of Dopamine]; COMT protein affects the reaction [Amphetamine results in increased abundance of Dopamine]
3,4-methylenedioxyethamphetamine inhibits the reaction [COMT protein results in increased methylation of Dopamine]; [entacapone results in decreased activity of COMT protein] which results in increased abundance of Dopamine; [tolcapone results in decreased activity of COMT protein] which results in increased abundance of Dopamine; N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine inhibits the reaction [COMT protein results in increased methylation of Dopamine]		 CTD PMID:7566641 PMID:11160877 PMID:11248589 PMID:12898346 PMID:14574438 More... NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642 		JBrowse link
G Cpt1a carnitine palmitoyltransferase 1A increases expression EXP Dopamine results in increased expression of CPT1A mRNA; Dopamine results in increased expression of CPT1A protein CTD PMID:8479178 NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055 		JBrowse link
G Creb1 cAMP responsive element binding protein 1 multiple interactions EXP [Dopamine binds to and results in increased activity of DRD1 protein] which results in increased phosphorylation of CREB1 protein; Calcium promotes the reaction [Dopamine results in increased phosphorylation of CREB1 protein]; Dizocilpine Maleate inhibits the reaction [Dopamine results in increased phosphorylation of CREB1 protein]; Dopamine binds to and results in increased activity of CREB1 protein; KN 62 inhibits the reaction [Dopamine results in increased phosphorylation of CREB1 protein]; SCH 23390 inhibits the reaction [[Dopamine binds to and results in increased activity of DRD1 protein] which results in increased phosphorylation of CREB1 protein] CTD PMID:14622123 NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816 		JBrowse link
G Cs citrate synthase increases expression ISO Dopamine results in increased expression of CS protein CTD PMID:24675778 NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421 		JBrowse link
G Ctsd cathepsin D increases expression ISO Dopamine results in increased expression of CTSD protein CTD PMID:24675778 NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488 		JBrowse link
G Cxcl9 C-X-C motif chemokine ligand 9 increases expression EXP Dopamine results in increased expression of CXCL9 mRNA CTD PMID:25818600 NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions
decreases activity		 ISO Dopamine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]
Dopamine results in decreased activity of CYP1A1 protein		 CTD PMID:18420780 PMID:18493746 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 decreases activity ISO Dopamine results in decreased activity of CYP1A2 protein CTD PMID:18420780 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 decreases activity ISO Dopamine results in decreased activity of CYP1B1 protein CTD PMID:18420780 NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917 		JBrowse link
G Cyp2c6 cytochrome P450, family 2, subfamily C, polypeptide 6 decreases activity ISO Dopamine results in decreased activity of CYP2C29 protein CTD PMID:18420780 NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596 		JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 decreases activity
increases abundance
multiple interactions		 ISO Dopamine results in decreased activity of CYP2D6 protein
CYP2D6 protein results in increased abundance of Dopamine
[CYP2D6 protein results in increased metabolism of Tyramine] which results in increased abundance of Dopamine		 CTD PMID:18420780 PMID:26763401 NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759 		JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 decreases activity ISO Dopamine results in decreased activity of CYP2E1 protein CTD PMID:18420780 NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 decreases activity ISO Dopamine results in decreased activity of CYP3A4 protein CTD PMID:18420780 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Dbh dopamine beta-hydroxylase affects abundance
multiple interactions		 ISO
EXP		 DBH gene polymorphism affects the abundance of Dopamine
DBH protein affects the reaction [Dopamine binds to DRD2 protein]		 CTD PMID:15716360 PMID:16163519 NCBI chr 3:10,488,260...10,505,245
Ensembl chr 3:10,488,260...10,505,248 		JBrowse link
G Disc1 DISC1 scaffold protein multiple interactions ISO DISC1 protein modified form results in increased uptake of and affects the metabolism of Dopamine CTD PMID:26754951 NCBI chr19:53,014,201...53,223,617
Ensembl chr19:53,014,616...53,219,778 		JBrowse link
G Drd1 dopamine receptor D1 multiple interactions
increases activity
affects localization		 ISO
EXP		 Dopamine binds to and results in increased activity of DRD1 protein; SCH 23390 inhibits the reaction [Dopamine affects the localization of DRD1 protein]; SCH 23390 inhibits the reaction [Dopamine results in increased activity of DRD1 protein]
[alpha-pyrrolidinovalerophenone results in increased secretion of Dopamine] results in increased activity of [DRD1 protein co-treated with DRD2 protein]
[Dopamine binds to and results in increased activity of DRD1 protein] which results in increased phosphorylation of CREB1 protein; [Dopamine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein; Dopamine deficiency inhibits the reaction [SCH 23390 binds to DRD1 protein]; DRD1 protein promotes the reaction [zonisamide affects the secretion of Dopamine]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dopamine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein]; SCH 23390 inhibits the reaction [[Dopamine binds to and results in increased activity of DRD1 protein] which results in increased phosphorylation of CREB1 protein]		 CTD PMID:12813475 PMID:14622123 PMID:15985612 PMID:19482038 PMID:22292096 More... NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002 		JBrowse link
G Drd2 dopamine receptor D2 multiple interactions
affects response to substance
increases activity
affects binding		 ISO
EXP		 [Dopamine co-treated with DRD2 protein alternative form] results in increased activity of RHOA protein; [Dopamine co-treated with Raclopride] promotes the reaction [Dopamine binds to DRD2 protein]; Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB1 protein]; Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB1 protein]]; GRK2 protein promotes the reaction [Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB2 protein]]
[alpha-pyrrolidinovalerophenone results in increased secretion of Dopamine] results in increased activity of [DRD1 protein co-treated with DRD2 protein]
DRD2 protein affects the susceptibility to Dopamine
Dopamine results in increased activity of DRD2 protein
[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine; [Raclopride binds to and results in decreased activity of DRD2 protein] which results in increased abundance of Dopamine; [Remoxipride results in decreased activity of DRD2 protein] inhibits the reaction [Dopamine results in decreased susceptibility to Pilocarpine]; Clozapine promotes the reaction [Dopamine binds to DRD2 protein]; Cocaine promotes the reaction [[DRD2 protein results in increased phosphorylation of TH protein] which results in increased abundance of Dopamine]; cypermethrin inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]; DBH protein affects the reaction [Dopamine binds to DRD2 protein]; decamethrin inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]; Dopamine promotes the reaction [Oxidopamine binds to DRD2 protein]; DRD2 mutant form inhibits the reaction [Dopamine results in decreased expression of IL10 protein]; DRD2 mutant form inhibits the reaction [Dopamine results in decreased expression of TGFB1 protein]; DRD2 mutant form inhibits the reaction [Dopamine results in decreased expression of VEGFA protein]; DRD2 mutant form inhibits the reaction [Dopamine results in increased expression of TNF protein]; DRD4 protein affects the reaction [Dopamine binds to DRD2 protein]; estradiol 3-benzoate inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]; Ethanol affects the reaction [Dopamine binds to DRD2 protein]; GRK6 protein affects the reaction [Dopamine binds to DRD2 protein]; Haloperidol inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]; Haloperidol promotes the reaction [Dopamine binds to DRD2 protein]; Olanzapine promotes the reaction [Dopamine binds to DRD2 protein]; Quetiapine Fumarate promotes the reaction [Dopamine binds to DRD2 protein]; Risperidone promotes the reaction [Dopamine binds to DRD2 protein]; Spiperone inhibits the reaction [Cocaine promotes the reaction [[DRD2 protein results in increased phosphorylation of TH protein] which results in increased abundance of Dopamine]]; tautomycin inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]; Tea inhibits the reaction [Dopamine promotes the reaction [Oxidopamine binds to DRD2 protein]]
Dopamine binds to DRD2 protein alternative form		 CTD PMID:8103596 PMID:10936494 PMID:12476322 PMID:15140183 PMID:15341276 More... NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875 		JBrowse link
G Drd3 dopamine receptor D3 increases activity
multiple interactions		 EXP
ISO		 Dopamine results in increased activity of DRD3 protein
Butaclamol inhibits the reaction [Dopamine results in increased activity of DRD3 protein]; Dopamine binds to and results in increased activity of DRD3 protein; Endocannabinoids promotes the reaction [Dopamine binds to and results in increased activity of DRD3 protein]
[Ionomycin co-treated with CAMK2A protein] inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]; [Raclopride binds to and results in decreased activity of DRD3 protein] which results in increased abundance of Dopamine; DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]; DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK3 protein]; NGB 2904 inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]; NGB 2904 inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK3 protein]]		 CTD PMID:15341276 PMID:19046384 PMID:19217379 PMID:30102254 PMID:31323226 NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596 		JBrowse link
G Drd4 dopamine receptor D4 multiple interactions
affects binding		 EXP
ISO		 DRD4 protein affects the reaction [Dopamine binds to DRD2 protein]
Dopamine binds to Drd4 protein
Clozapine inhibits the reaction [Dopamine results in increased activity of DRD4 protein]; Dopamine binds to and results in increased activity of DRD4 protein; Endocannabinoids inhibits the reaction [Dopamine binds to and results in increased activity of DRD4 protein]		 CTD
RGD		 PMID:15716360 PMID:30102254 PMID:31323226 PMID:8078498 RGD:7248459 NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553 		JBrowse link
G Drd5 dopamine receptor D5 increases expression EXP Dopamine results in increased expression of DRD5 mRNA CTD PMID:18522901 NCBI chr14:72,487,950...72,491,050
Ensembl chr14:72,489,347...72,490,774 		JBrowse link
G Ecm2 extracellular matrix protein 2 decreases expression EXP Dopamine results in decreased expression of ECM2 mRNA CTD PMID:21983523 NCBI chr17:15,120,194...15,152,536
Ensembl chr17:15,120,196...15,152,516 		JBrowse link
G Eef1a1 eukaryotic translation elongation factor 1 alpha 1 increases expression ISO Dopamine results in increased expression of EEF1A1 protein CTD PMID:24675778 NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839 		JBrowse link
G Efhd2 EF-hand domain family, member D2 multiple interactions
decreases secretion		 ISO [EFHD2 gene mutant form affects the susceptibility to Ethanol] which results in increased secretion of Dopamine
EFHD2 gene mutant form results in decreased secretion of Dopamine		 CTD PMID:28397836 NCBI chr 5:154,160,945...154,176,980
Ensembl chr 5:154,160,946...154,176,980 		JBrowse link
G En1 engrailed homeobox 1 multiple interactions ISO [EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]; [EN1 protein co-treated with EN2 protein] results in increased abundance of Dopamine; NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]] CTD PMID:21892157 NCBI chr13:31,750,892...31,756,477
Ensembl chr13:31,751,545...31,755,943 		JBrowse link
G En2 engrailed homeobox 2 multiple interactions ISO [EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]; [EN1 protein co-treated with EN2 protein] results in increased abundance of Dopamine; NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]] CTD PMID:21892157 NCBI chr 4:7,221,096...7,226,943
Ensembl chr 4:7,221,096...7,226,943 		JBrowse link
G Eng endoglin decreases expression EXP Dopamine results in decreased expression of ENG mRNA CTD PMID:21983523 NCBI chr 3:15,934,566...15,972,618
Ensembl chr 3:15,934,518...15,973,230 		JBrowse link
G Enpp3 ectonucleotide pyrophosphatase/phosphodiesterase 3 increases expression EXP Dopamine results in increased expression of ENPP3 mRNA CTD PMID:21983523 NCBI chr 1:20,563,700...20,635,044
Ensembl chr 1:20,563,697...20,635,041 		JBrowse link
G Erp29 endoplasmic reticulum protein 29 increases expression EXP Dopamine results in increased expression of ERP29 mRNA CTD PMID:21983523 NCBI chr12:35,089,698...35,095,952
Ensembl chr12:35,089,707...35,096,376 		JBrowse link
G F3 coagulation factor III, tissue factor multiple interactions ISO Dopamine promotes the reaction [TNF protein results in increased expression of F3 mRNA] CTD PMID:20118172 NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668 		JBrowse link
G Fn1 fibronectin 1 increases expression EXP Dopamine results in increased expression of FN1 mRNA CTD PMID:21983523 NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678 		JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions
increases expression		 ISO
EXP		 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; [Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA; [Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein; bisindolylmaleimide I inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; Bupropion inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA]; Bupropion inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; Cocaine inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA]; Cocaine inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA]; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]
Dopamine results in increased expression of FOS mRNA; Dopamine results in increased expression of FOS protein		 CTD PMID:10700011 PMID:12112414 PMID:19217379 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036 		JBrowse link
G G6pd glucose-6-phosphate dehydrogenase increases activity
decreases activity
multiple interactions		 EXP Dopamine results in increased activity of G6PD protein
Dopamine results in decreased activity of G6PD protein
Atenolol inhibits the reaction [Dopamine results in increased activity of G6PD protein]		 CTD PMID:1978808 PMID:26820767 NCBI chr  X:152,201,081...152,220,863
Ensembl chr  X:152,201,098...152,220,801 		JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase increases expression ISO Dopamine results in increased expression of GAPDH protein CTD PMID:24675778 NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235 		JBrowse link
G Gch1 GTP cyclohydrolase 1 increases abundance EXP GCH1 protein results in increased abundance of Dopamine CTD PMID:15929554 NCBI chr15:20,404,267...20,437,727
Ensembl chr15:20,402,527...20,437,698 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions ISO Dopamine promotes the reaction [Zinc deficiency results in increased cleavage of GCLC protein] CTD PMID:23377617 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544 		JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit multiple interactions ISO [GCLM gene mutant form results in increased susceptibility to Paraquat] which results in decreased abundance of Dopamine CTD PMID:23704229 NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535 		JBrowse link
G Gdnf glial cell derived neurotrophic factor multiple interactions
increases metabolic processing		 ISO
EXP		 GDNF protein inhibits the reaction [Oxidopamine results in decreased secretion of Dopamine]
GDNF protein results in increased metabolism of Dopamine		 CTD PMID:12213621 PMID:15269253 NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209 		JBrowse link
G Ghrl ghrelin and obestatin prepropeptide decreases export EXP GHRL protein results in decreased export of Dopamine CTD PMID:20553917 NCBI chr 4:146,865,712...146,869,621
Ensembl chr 4:146,865,712...146,869,621 		JBrowse link
G Gnrh1 gonadotropin releasing hormone 1 multiple interactions EXP Dopamine affects the reaction [manganese chloride results in increased secretion of GNRH1 protein] CTD PMID:18603625 NCBI chr15:41,972,482...41,976,690
Ensembl chr15:41,972,905...41,973,581
Ensembl chr15:41,972,905...41,973,581 		JBrowse link
G Gria1 glutamate ionotropic receptor AMPA type subunit 1 increases localization EXP Dopamine results in increased localization of GRIA1 protein CTD PMID:19674091 NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283 		JBrowse link
G Gria2 glutamate ionotropic receptor AMPA type subunit 2 increases localization EXP Dopamine results in increased localization of GRIA2 protein CTD PMID:19674091 NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510 		JBrowse link
G Grin1 glutamate ionotropic receptor NMDA type subunit 1 multiple interactions EXP [Dopamine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dopamine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein] CTD PMID:14622123 NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603 		JBrowse link
G Grk2 G protein-coupled receptor kinase 2 multiple interactions ISO GRK2 protein promotes the reaction [Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB1 protein]]; GRK2 protein promotes the reaction [Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB2 protein]] CTD PMID:31024316 NCBI chr 1:201,580,823...201,601,580
Ensembl chr 1:201,581,480...201,601,582 		JBrowse link
G Grk6 G protein-coupled receptor kinase 6 multiple interactions EXP GRK6 protein affects the reaction [Dopamine binds to DRD2 protein] CTD PMID:15716360 NCBI chr17:9,177,018...9,192,813
Ensembl chr17:9,177,019...9,192,644 		JBrowse link
G Grm5 glutamate metabotropic receptor 5 multiple interactions EXP [6-methyl-2-(phenylethynyl)pyridine binds to and results in decreased activity of GRM5 protein] inhibits the reaction [Methamphetamine results in decreased abundance of Dopamine]; [6-methyl-2-(phenylethynyl)pyridine binds to and results in decreased activity of GRM5 protein] inhibits the reaction [Methamphetamine results in increased secretion of Dopamine]; [6-methyl-2-(phenylethynyl)pyridine binds to and results in decreased activity of GRM5 protein] inhibits the reaction [Veratridine results in increased secretion of Dopamine]; [6-methyl-2-(phenylethynyl)pyridine binds to and results in decreased activity of GRM5 protein] which results in decreased secretion of Dopamine CTD PMID:12907309 NCBI chr 1:141,310,069...141,884,980
Ensembl chr 1:141,312,368...141,882,274 		JBrowse link
G Gsr glutathione-disulfide reductase decreases activity EXP Dopamine results in decreased activity of GSR protein CTD PMID:26820767 NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661 		JBrowse link
G Gsta1 glutathione S-transferase alpha 1 decreases activity ISO Dopamine analog results in decreased activity of GSTA1 protein CTD PMID:8131222 NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121 		JBrowse link
G Gstm1 glutathione S-transferase mu 1 decreases activity ISO Dopamine analog results in decreased activity of GSTM1 protein CTD PMID:8131222 NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411 		JBrowse link
G Gstp1 glutathione S-transferase pi 1 decreases activity ISO Dopamine analog results in decreased activity of GSTP1 protein CTD PMID:8131222 NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226 		JBrowse link
G H1f5 H1.5 linker histone, cluster member increases expression ISO Dopamine results in increased expression of H1-5 protein CTD PMID:24675778 NCBI chr17:42,726,132...42,727,162
Ensembl chr17:42,726,127...42,769,160 		JBrowse link
G Hcrtr1 hypocretin receptor 1 multiple interactions EXP [1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea binds to and results in decreased activity of HCRTR1 protein] inhibits the reaction [Amphetamine results in increased secretion of Dopamine] CTD PMID:19737591 NCBI chr 5:142,477,214...142,486,674
Ensembl chr 5:142,477,214...142,486,674 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha increases expression
multiple interactions
decreases expression		 ISO
EXP		 [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BBC3 mRNA; [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BBC3 protein; [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BNIP3 mRNA; [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BNIP3 protein; [Dopamine results in increased expression of HIF1A protein] which results in increased expression of TP53 protein; Dopamine results in increased expression of HIF1A protein
Clodronic Acid inhibits the reaction [Dopamine results in decreased expression of HIF1A protein]; eticlopride inhibits the reaction [Dopamine results in decreased expression of HIF1A protein]; zoledronic acid inhibits the reaction [Dopamine results in decreased expression of HIF1A protein]
[Dopamine results in increased expression of HIF1A protein] which results in increased expression of and results in increased phosphorylation of TP53 protein; Acetylcysteine inhibits the reaction [Dopamine results in increased expression of HIF1A protein]		 CTD PMID:19410601 PMID:25818600 NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261 		JBrowse link
G Hmgcs2 3-hydroxy-3-methylglutaryl-CoA synthase 2 decreases expression EXP Dopamine results in decreased expression of HMGCS2 mRNA CTD PMID:21983523 NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130 		JBrowse link
G Hmox1 heme oxygenase 1 increases expression
multiple interactions		 EXP
ISO		 [Dopamine results in increased expression of HMOX1 mRNA] which results in increased expression of SOD2 mRNA; Dopamine results in increased expression of HMOX1 mRNA
[SNCA protein co-treated with Dopamine] results in increased expression of HMOX1 protein; [SNCA protein co-treated with Paraquat co-treated with Dopamine] results in increased expression of HMOX1 protein; HMOX1 protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased abundance of Dopamine]		 CTD PMID:10942521 PMID:18799798 PMID:21735318 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079 		JBrowse link
G Hrh1 histamine receptor H 1 multiple interactions EXP [1-phenyl-3-dimethylamino-1,2,3,4-tetrahydronaphthalene analog binds to and results in increased activity of HRH1 protein] promotes the reaction [TH protein results in increased chemical synthesis of Dopamine] CTD PMID:10661506 NCBI chr 4:147,564,963...147,649,353
Ensembl chr 4:147,645,995...147,647,455 		JBrowse link
G Hsp90ab1 heat shock protein 90 alpha family class B member 1 increases expression ISO Dopamine results in increased expression of HSP90AB1 protein CTD PMID:24675778 NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488 		JBrowse link
G Hsp90b1 heat shock protein 90 beta family member 1 increases expression ISO Dopamine results in increased expression of HSP90B1 protein CTD PMID:24675778 NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 increases expression ISO Dopamine results in increased expression of HSPA5 protein CTD PMID:24675778 NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891 		JBrowse link
G Hspa6l-ps1 heat shock protein family A (Hsp70) member 6 like, pseudogene 1 increases expression ISO Dopamine results in increased expression of HSPA6 protein CTD PMID:24675778 NCBI chr13:83,273,176...83,274,317 JBrowse link
G Hspa9 heat shock protein family A (Hsp70) member 9 increases expression ISO Dopamine results in increased expression of HSPA9 protein CTD PMID:24675778 NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292 		JBrowse link
G Htr2a 5-hydroxytryptamine receptor 2A multiple interactions EXP [4-iodo-2,5-dimethoxyphenylisopropylamine binds to and results in increased activity of HTR2A protein] which results in increased secretion of and results in increased abundance of Dopamine; Cocaine promotes the reaction [[4-iodo-2,5-dimethoxyphenylisopropylamine binds to and results in increased activity of HTR2A protein] which results in increased secretion of and results in increased abundance of Dopamine]; Ketanserin inhibits the reaction [[4-iodo-2,5-dimethoxyphenylisopropylamine binds to and results in increased activity of HTR2A protein] which results in increased secretion of and results in increased abundance of Dopamine]; Ketanserin inhibits the reaction [Cocaine promotes the reaction [[4-iodo-2,5-dimethoxyphenylisopropylamine binds to and results in increased activity of HTR2A protein] which results in increased secretion of and results in increased abundance of Dopamine]] CTD PMID:10773215 NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928 		JBrowse link
G Htr2c 5-hydroxytryptamine receptor 2C multiple interactions ISO HTR2C protein affects the reaction [Cocaine results in increased abundance of Dopamine] CTD PMID:12427861 NCBI chr  X:110,640,777...110,870,288
Ensembl chr  X:110,641,153...110,870,287 		JBrowse link
G Htr3a 5-hydroxytryptamine receptor 3A multiple interactions ISO Dopamine binds to and results in increased activity of [HTR3A protein binds to HTR3A protein]; Dopamine binds to and results in increased activity of [HTR3A protein binds to HTR3B protein] CTD PMID:17360702 NCBI chr 8:49,242,018...49,254,475
Ensembl chr 8:49,242,020...49,254,389 		JBrowse link
G Htr3b 5-hydroxytryptamine receptor 3B multiple interactions ISO Dopamine binds to and results in increased activity of [HTR3A protein binds to HTR3B protein] CTD PMID:17360702 NCBI chr 8:49,279,291...49,308,444
Ensembl chr 8:49,279,173...49,308,444 		JBrowse link
G Il10 interleukin 10 decreases expression
multiple interactions		 EXP Dopamine results in decreased expression of IL10 mRNA; Dopamine results in decreased expression of IL10 protein
DRD2 mutant form inhibits the reaction [Dopamine results in decreased expression of IL10 protein]; eticlopride inhibits the reaction [Dopamine results in decreased expression of IL10 protein]		 CTD PMID:25818600 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313 		JBrowse link
G Ins2 insulin 2 multiple interactions
increases secretion
increases expression		 ISO Dopamine promotes the reaction [Metoclopramide results in increased expression of INS protein]
Dopamine results in increased secretion of INS protein
Dopamine results in increased expression of INS protein		 CTD PMID:18645345 NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit increases phosphorylation
multiple interactions		 ISO Dopamine results in increased phosphorylation of JUN protein
PRKN protein inhibits the reaction [Dopamine results in increased phosphorylation of JUN protein]		 CTD PMID:15198987 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656 		JBrowse link
G Kcna1 potassium voltage-gated channel subfamily A member 1 multiple interactions EXP KCNA1 protein affects the reaction [Amphetamine results in increased secretion of Dopamine] CTD PMID:12700677 NCBI chr 4:159,464,223...159,472,905
Ensembl chr 4:159,464,188...159,472,682 		JBrowse link
G Kcnj6 potassium inwardly-rectifying channel, subfamily J, member 6 decreases abundance ISO KCNJ6 gene mutant form results in decreased abundance of Dopamine CTD PMID:15256069 NCBI chr11:34,061,702...34,308,758
Ensembl chr11:34,061,708...34,308,758 		JBrowse link
G Kdelr3 KDEL endoplasmic reticulum protein retention receptor 3 increases expression EXP Dopamine results in increased expression of KDELR3 mRNA CTD PMID:21983523 NCBI chr 7:111,079,236...111,089,463
Ensembl chr 7:111,079,218...111,101,600 		JBrowse link
G Kpna2 karyopherin subunit alpha 2 increases expression EXP Dopamine results in increased expression of KPNA2 mRNA CTD PMID:21983523 NCBI chr10:91,933,951...91,946,115
Ensembl chr10:91,933,951...91,946,150 		JBrowse link
G Lgmn legumain increases expression EXP Dopamine results in increased expression of LGMN mRNA CTD PMID:21983523 NCBI chr 6:121,544,048...121,582,495
Ensembl chr 6:121,544,053...121,582,480 		JBrowse link
G Litaf lipopolysaccharide-induced TNF factor increases expression EXP Dopamine results in increased expression of LITAF mRNA CTD PMID:21983523 NCBI chr10:4,656,308...4,692,981
Ensembl chr10:4,625,552...4,692,763 		JBrowse link
G Lmna lamin A/C increases expression ISO Dopamine results in increased expression of LMNA protein CTD PMID:24675778 NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423 		JBrowse link
G Loxl2 lysyl oxidase-like 2 increases expression EXP Dopamine results in increased expression of LOXL2 mRNA CTD PMID:21983523 NCBI chr15:44,683,449...44,773,067
Ensembl chr15:44,683,880...44,773,067 		JBrowse link
G Lrat lecithin retinol acyltransferase increases expression EXP Dopamine results in increased expression of LRAT mRNA CTD PMID:21983523 NCBI chr 2:168,264,093...168,273,155
Ensembl chr 2:168,266,877...168,273,619 		JBrowse link
G Lrrk2 leucine-rich repeat kinase 2 multiple interactions ISO LRRK2 mutant form results in increased susceptibility to [Dopamine co-treated with SLC6A3 protein] CTD PMID:23628791 NCBI chr 7:122,826,696...122,987,711
Ensembl chr 7:122,826,696...122,987,703 		JBrowse link
G Maoa monoamine oxidase A increases abundance
decreases amination
multiple interactions		 ISO MAOA mutant form results in increased abundance of Dopamine
MAOA protein results in decreased amination of Dopamine
3,4-Methylenedioxyamphetamine inhibits the reaction [MAOA protein results in decreased amination of Dopamine]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [MAOA protein results in decreased amination of Dopamine]		 CTD PMID:11834493 PMID:26721607 NCBI chr  X:6,032,172...6,098,308
Ensembl chr  X:6,030,795...6,099,593 		JBrowse link
G Maob monoamine oxidase B multiple interactions
increases degradation
decreases amination		 EXP
ISO		 [Ro 16-6491 results in decreased activity of MAOB protein] which results in decreased susceptibility to Dopamine; [Selegiline results in decreased activity of MAOB protein] which results in increased abundance of Dopamine
MAOB protein results in increased degradation of Dopamine
1-(8-bromobenzo(1,2-b;4,5-b')difuran-4-yl)-2-aminopropane inhibits the reaction [MAOB protein results in increased degradation of Dopamine]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [MAOB protein results in decreased amination of Dopamine]; Selegiline inhibits the reaction [MAOB protein results in decreased amination of Dopamine]; Selegiline inhibits the reaction [MAOB protein results in increased degradation of Dopamine]		 CTD PMID:16012872 PMID:20875051 PMID:26721607 PMID:30036687 NCBI chr  X:5,907,327...6,010,996
Ensembl chr  X:5,907,266...6,011,003 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation		 ISO
EXP		 Dopamine results in increased phosphorylation of and results in increased activity of MAPK1 protein; RGS3 protein affects the reaction [Dopamine results in increased phosphorylation of and results in increased activity of MAPK1 protein]
[Ionomycin co-treated with CAMK2A protein] inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]; DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]; NGB 2904 inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]		 CTD PMID:16760913 PMID:18977218 PMID:19217379 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation		 ISO
EXP		 Dopamine results in increased phosphorylation of and results in increased activity of MAPK3 protein; RGS3 protein affects the reaction [Dopamine results in increased phosphorylation of and results in increased activity of MAPK3 protein]
DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK3 protein]; NGB 2904 inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK3 protein]]		 CTD PMID:16760913 PMID:18977218 PMID:19217379 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions
increases phosphorylation		 ISO Acetylcysteine inhibits the reaction [Dopamine results in increased phosphorylation of MAPK8 protein]; Glutathione inhibits the reaction [Dopamine results in increased phosphorylation of MAPK8 protein] CTD PMID:17481858 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981 		JBrowse link
G Mapt microtubule-associated protein tau multiple interactions ISO Dopamine metabolite promotes the reaction [MAPT protein binds to MAPT protein]; Dopamine promotes the reaction [MAPT protein binds to MAPT protein] CTD PMID:16180106 NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129 		JBrowse link
G Marcks myristoylated alanine rich protein kinase C substrate increases expression ISO Dopamine results in increased expression of MARCKS protein CTD PMID:24675778 NCBI chr20:40,685,315...40,691,012
Ensembl chr20:40,685,315...40,691,012 		JBrowse link
G Mrc1 mannose receptor, C type 1 decreases expression EXP Dopamine results in decreased expression of MRC1 mRNA; Dopamine results in decreased expression of MRC1 protein CTD PMID:25818600 NCBI chr17:77,249,187...77,330,857
Ensembl chr17:77,249,187...77,330,857 		JBrowse link
G Mt1 metallothionein 1 multiple interactions ISO [MT1 co-treated with Dopamine] results in decreased abundance of semiquinone radicals; [MT1 gene mutant form co-treated with MT2 gene mutant form co-treated with Mercuric Chloride] results in decreased abundance of Dopamine CTD PMID:17910954 PMID:18226494 NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
Ensembl chr17:10,826,032...10,827,049 		JBrowse link
G Mt2A metallothionein 2A multiple interactions ISO [MT1 gene mutant form co-treated with MT2 gene mutant form co-treated with Mercuric Chloride] results in decreased abundance of Dopamine CTD PMID:18226494 NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784 		JBrowse link
G Mtor mechanistic target of rapamycin kinase decreases phosphorylation ISO Dopamine results in decreased phosphorylation of MTOR protein CTD PMID:19410601 NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311 		JBrowse link
G Mtr 5-methyltetrahydrofolate-homocysteine methyltransferase multiple interactions
increases activity		 ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Dopamine results in increased activity of MTR protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Dopamine results in increased activity of MTR protein]; Ethanol promotes the reaction [Dopamine results in increased activity of MTR protein]; wortmannin inhibits the reaction [Dopamine results in increased activity of MTR protein] CTD PMID:14745455 NCBI chr17:58,219,998...58,308,560
Ensembl chr17:58,220,071...58,304,822 		JBrowse link
G Myct1 myc target 1 decreases expression EXP Dopamine results in decreased expression of MYCT1 mRNA CTD PMID:21983523 NCBI chr 1:42,018,137...42,029,410
Ensembl chr 1:42,018,137...42,029,410 		JBrowse link
G Ncl nucleolin increases expression ISO Dopamine results in increased expression of NCL protein CTD PMID:24675778 NCBI chr 9:86,999,588...87,008,112
Ensembl chr 9:86,998,019...87,008,136 		JBrowse link
G Ndufs1 NADH:ubiquinone oxidoreductase core subunit S1 multiple interactions ISO NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]] CTD PMID:21892157 NCBI chr 9:64,546,430...64,579,751
Ensembl chr 9:64,546,225...64,579,893 		JBrowse link
G Ndufs4 NADH:ubiquinone oxidoreductase subunit S4 multiple interactions ISO NDUFS4 protein affects the reaction [Rotenone results in increased abundance of Dopamine]; Paclitaxel inhibits the reaction [NDUFS4 protein affects the reaction [Rotenone results in increased abundance of Dopamine]] CTD PMID:21383081 NCBI chr 2:45,951,327...46,061,829
Ensembl chr 2:45,951,313...46,061,846 		JBrowse link
G Nfkbiz NFKB inhibitor zeta increases expression EXP Dopamine results in increased expression of NFKBIZ mRNA CTD PMID:21983523 NCBI chr11:44,782,676...44,810,722
Ensembl chr11:44,782,676...44,810,723 		JBrowse link
G Nos1 nitric oxide synthase 1 multiple interactions ISO NOS1 protein affects the reaction [Methamphetamine results in decreased abundance of Dopamine] CTD PMID:11085313 PMID:20575850 NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945 		JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions
increases expression		 ISO
EXP		 Atenolol inhibits the reaction [Dopamine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Dopamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; carvedilol inhibits the reaction [Dopamine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; carvedilol inhibits the reaction [Dopamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Dopamine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]; Dopamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Prazosin inhibits the reaction [Dopamine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Prazosin inhibits the reaction [Dopamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]
Dopamine results in increased expression of NOS2 mRNA; Dopamine results in increased expression of NOS2 protein		 CTD PMID:19439816 PMID:25818600 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210 		JBrowse link
G Nppc natriuretic peptide C multiple interactions EXP NPPC protein inhibits the reaction [Cocaine results in increased abundance of Dopamine] CTD PMID:11860464 NCBI chr 9:87,320,051...87,324,251
Ensembl chr 9:87,320,051...87,324,251 		JBrowse link
G Nr3c1 nuclear receptor subfamily 3, group C, member 1 increases abundance
multiple interactions		 ISO NR3C1 protein results in increased abundance of Dopamine
[RU 43044 binds to and results in decreased activity of NR3C1 protein] inhibits the reaction [Methamphetamine results in increased secretion of Dopamine]		 CTD PMID:11226678 PMID:18925659 NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375 		JBrowse link
G Nrip3 nuclear receptor interacting protein 3 increases expression EXP Dopamine results in increased expression of NRIP3 mRNA CTD PMID:21983523 NCBI chr 1:163,789,738...163,815,036
Ensembl chr 1:163,789,738...163,815,600 		JBrowse link
G Ntf3 neurotrophin 3 increases expression EXP Dopamine results in increased expression of NTF3 mRNA; Dopamine results in increased expression of NTF3 protein CTD PMID:19854260 NCBI chr 4:158,914,984...158,984,453
Ensembl chr 4:158,914,957...158,984,596 		JBrowse link
G Omd osteomodulin decreases expression EXP Dopamine results in decreased expression of OMD mRNA CTD PMID:21983523 NCBI chr17:15,060,217...15,068,441
Ensembl chr17:15,060,217...15,068,441 		JBrowse link
G Oprk1 opioid receptor, kappa 1 multiple interactions EXP [U 69593 binds to and results in increased activity of OPRK1 protein] inhibits the reaction [Cocaine affects the abundance of Dopamine] CTD PMID:11113311 NCBI chr 5:13,860,016...13,877,823
Ensembl chr 5:13,860,021...13,877,823 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage		 ISO Dopamine promotes the reaction [Zinc deficiency results in increased cleavage of PARP1 protein]; PRKN protein inhibits the reaction [Dopamine results in increased cleavage of PARP1 protein]; resveratrol inhibits the reaction [Dopamine results in increased cleavage of PARP1 protein]; Zinc deficiency promotes the reaction [Dopamine results in increased cleavage of PARP1 protein]
[PARP1 protein results in increased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] which results in increased abundance of Dopamine		 CTD PMID:10318960 PMID:15198987 PMID:17603292 PMID:19410601 PMID:22987761 More... NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pcmt1 protein-L-isoaspartate (D-aspartate) O-methyltransferase 1 multiple interactions
decreases expression		 ISO 1,3-dimethylthiourea inhibits the reaction [Dopamine results in decreased expression of PCMT1 mRNA]; Acetylcysteine inhibits the reaction [Dopamine results in decreased expression of PCMT1 mRNA]; Acetylcysteine inhibits the reaction [Dopamine results in decreased expression of PCMT1 protein]
Dopamine results in decreased expression of PCMT1 mRNA; Dopamine results in decreased expression of PCMT1 protein		 CTD PMID:24631677 NCBI chr 1:2,111,756...2,160,354
Ensembl chr 1:2,111,763...2,159,201 		JBrowse link
G Pdia3 protein disulfide isomerase family A, member 3 decreases expression ISO Dopamine results in decreased expression of PDIA3 protein CTD PMID:24675778 NCBI chr 3:108,388,189...108,412,013
Ensembl chr 3:108,388,245...108,413,236 		JBrowse link
G Pdia6 protein disulfide isomerase family A, member 6 increases expression EXP Dopamine results in increased expression of PDIA6 mRNA CTD PMID:21983523 NCBI chr 6:40,062,980...40,080,223
Ensembl chr 6:40,062,926...40,080,613 		JBrowse link
G Pgd phosphogluconate dehydrogenase decreases activity EXP Dopamine results in decreased activity of PGD protein CTD PMID:26820767 NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778 		JBrowse link
G Pgk1 phosphoglycerate kinase 1 decreases expression EXP Dopamine results in decreased expression of PGK1 mRNA CTD PMID:21983523 NCBI chr  X:71,271,454...71,287,429
Ensembl chr  X:71,271,440...71,287,418 		JBrowse link
G Phb1 prohibitin 1 increases expression ISO Dopamine results in increased expression of PHB1 protein CTD PMID:24675778 NCBI chr10:80,605,268...80,618,043
Ensembl chr10:80,605,251...80,618,042 		JBrowse link
G Pink1 PTEN induced kinase 1 multiple interactions
affects abundance		 ISO [PINK1 mutant form results in increased susceptibility to Paraquat] which results in decreased abundance of Dopamine; Paraquat affects the reaction [PINK1 protein affects the abundance of Dopamine] CTD PMID:22043175 NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635 		JBrowse link
G Pkm pyruvate kinase M1/2 increases expression ISO Dopamine results in increased expression of PKM protein CTD PMID:24675778 NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599 		JBrowse link
G Pld3 phospholipase D family, member 3 affects expression ISO Dopamine affects the expression of PLD3 protein CTD PMID:24675778 NCBI chr 1:82,821,863...82,844,280
Ensembl chr 1:82,821,875...82,844,072 		JBrowse link
G Plp2 proteolipid protein 2 increases expression EXP Dopamine results in increased expression of PLP2 mRNA CTD PMID:21983523 NCBI chr  X:14,834,249...14,837,648
Ensembl chr  X:14,834,231...14,838,514 		JBrowse link
G Pomc proopiomelanocortin multiple interactions ISO POMC protein affects the reaction [Nicotine results in increased abundance of Dopamine] CTD PMID:15689546 NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664 		JBrowse link
G Potef POTE ankyrin domain family, member F increases expression ISO Dopamine results in increased expression of POTEF protein CTD PMID:24675778 NCBI chr18:23,626,518...23,629,132
Ensembl chr 3:72,977,767...72,979,694 		JBrowse link
G Prdx3 peroxiredoxin 3 increases expression ISO Dopamine results in increased expression of PRDX3 protein CTD PMID:24675778 NCBI chr 1:260,001,642...260,014,064
Ensembl chr 1:260,001,637...260,014,111 		JBrowse link
G Prkcd protein kinase C, delta multiple interactions ISO [rottlerin results in decreased activity of PRKCD protein] inhibits the reaction [Methamphetamine results in increased metabolism of Dopamine]; PRKCD protein affects the reaction [Methamphetamine results in increased metabolism of Dopamine] CTD PMID:22512859 NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352 		JBrowse link
G Prkn parkin RBR E3 ubiquitin protein ligase multiple interactions
increases expression		 ISO PRKN protein inhibits the reaction [Dopamine results in increased abundance of Reactive Oxygen Species]; PRKN protein inhibits the reaction [Dopamine results in increased cleavage of CASP3 protein]; PRKN protein inhibits the reaction [Dopamine results in increased cleavage of PARP1 protein]; PRKN protein inhibits the reaction [Dopamine results in increased phosphorylation of JUN protein]
PRKN mutant form results in increased abundance of and results in increased metabolism of Dopamine; PRKN protein affects the abundance of and affects the metabolism of Dopamine; PRKN protein promotes the reaction [Amphetamine results in increased abundance of Dopamine]
Dopamine results in increased expression of PRKN mRNA		 CTD PMID:12915482 PMID:15198987 PMID:15993444 PMID:16987221 NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555 		JBrowse link
G Prl prolactin multiple interactions
decreases secretion
decreases expression		 ISO
EXP		 [Raloxifene Hydrochloride co-treated with Dopamine] results in decreased expression of PRL protein; Domperidone inhibits the reaction [Dopamine results in decreased expression of PRL protein]
Haloperidol inhibits the reaction [Dopamine results in decreased secretion of PRL protein]; Risperidone inhibits the reaction [Dopamine results in decreased secretion of PRL protein]		 CTD PMID:1380082 PMID:8532072 PMID:30865525 NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062 		JBrowse link
G Pros1 protein S increases expression EXP Dopamine results in increased expression of PROS1 mRNA CTD PMID:21983523 NCBI chr11:230,597...311,288
Ensembl chr11:230,696...311,286 		JBrowse link
G Ptrh1 peptidyl-tRNA hydrolase 1 homolog increases expression EXP Dopamine results in increased expression of PTRH1 mRNA CTD PMID:21983523 NCBI chr 3:16,064,867...16,071,098
Ensembl chr 3:16,064,880...16,070,648 		JBrowse link
G Rack1 receptor for activated C kinase 1 increases expression ISO Dopamine results in increased expression of RACK1 protein CTD PMID:24675778 NCBI chr10:33,169,415...33,174,896
Ensembl chr10:33,169,169...33,174,975 		JBrowse link
G Ran RAN, member RAS oncogene family increases expression EXP Dopamine results in increased expression of RAN mRNA CTD PMID:21983523 NCBI chr12:27,674,049...27,678,598
Ensembl chr12:27,674,050...27,678,276 		JBrowse link
G Rangap1 RAN GTPase activating protein 1 increases expression EXP Dopamine results in increased expression of RANGAP1 mRNA CTD PMID:21983523 NCBI chr 7:113,224,695...113,250,441
Ensembl chr 7:113,224,703...113,250,438 		JBrowse link
G Rgs3 regulator of G-protein signaling 3 multiple interactions ISO RGS3 protein affects the reaction [Dopamine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RGS3 protein affects the reaction [Dopamine results in increased phosphorylation of and results in increased activity of MAPK3 protein] CTD PMID:18977218 NCBI chr 5:76,022,038...76,161,895
Ensembl chr 5:76,022,001...76,161,894 		JBrowse link
G Rhoa ras homolog family member A multiple interactions ISO [Dopamine co-treated with DRD2 protein alternative form] results in increased activity of RHOA protein CTD PMID:27717053 NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746 		JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 decreases phosphorylation ISO Dopamine results in decreased phosphorylation of RPS6KB1 protein CTD PMID:19410601 NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908 		JBrowse link
G Rpsa ribosomal protein SA increases expression ISO Dopamine results in increased expression of RPSA protein CTD PMID:24675778 NCBI chr 8:119,851,225...119,855,103
Ensembl chr 8:119,851,225...119,855,247 		JBrowse link
G Ruvbl1 RuvB-like AAA ATPase 1 increases expression ISO Dopamine results in increased expression of RUVBL1 protein CTD PMID:24675778 NCBI chr 4:120,932,486...120,967,400
Ensembl chr 4:120,932,417...121,029,384 		JBrowse link
G S100a11 S100 calcium binding protein A11 increases expression EXP Dopamine results in increased expression of S100A11 mRNA CTD PMID:21983523 NCBI chr 2:179,191,688...179,197,098
Ensembl chr 2:179,191,715...179,197,044 		JBrowse link
G S100a4 S100 calcium-binding protein A4 increases expression EXP Dopamine results in increased expression of S100A4 mRNA CTD PMID:21983523 NCBI chr 2:176,090,951...176,093,258
Ensembl chr 2:176,091,804...176,093,254 		JBrowse link
G Sct secretin increases metabolic processing ISO SCT protein results in increased metabolism of Dopamine CTD PMID:16168596 NCBI chr 1:196,382,857...196,383,668
Ensembl chr 1:196,382,856...196,383,658 		JBrowse link
G Septin9 septin 9 decreases expression ISO Dopamine results in decreased expression of SEPTIN9 protein CTD PMID:24675778 NCBI chr10:102,409,798...102,579,056
Ensembl chr10:102,409,711...102,579,055 		JBrowse link
G Shmt2 serine hydroxymethyltransferase 2 increases expression ISO Dopamine results in increased expression of SHMT2 protein CTD PMID:24675778 NCBI chr 7:63,358,961...63,364,293
Ensembl chr 7:63,358,961...63,364,236 		JBrowse link
G Slc18a1 solute carrier family 18 member A1 multiple interactions ISO Dopamine inhibits the reaction [SLC18A1 protein results in increased uptake of Serotonin] CTD PMID:8245983 NCBI chr16:20,653,268...20,687,051
Ensembl chr16:20,653,508...20,687,051 		JBrowse link
G Slc18a2 solute carrier family 18 member A2 multiple interactions
increases uptake
decreases activity
affects binding
decreases abundance		 ISO
EXP		 Heptachlor Epoxide inhibits the reaction [SLC18A2 protein results in increased uptake of Dopamine]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [SLC18A2 protein results in increased uptake of Dopamine]; para-methyl-4-methylaminorex inhibits the reaction [SLC18A2 protein results in increased uptake of Dopamine]; Reserpine inhibits the reaction [SLC18A2 protein results in increased uptake of Dopamine]
DDT inhibits the reaction [SLC18A2 protein results in increased uptake of Dopamine]; Dichlorodiphenyldichloroethane inhibits the reaction [SLC18A2 protein results in increased uptake of Dopamine]; SLC18A2 protein affects the transport of and affects the abundance of Dopamine
Dopamine inhibits the reaction [SLC18A2 protein results in increased uptake of Serotonin]
Dopamine results in decreased activity of SLC18A2 protein
Dopamine binds to SLC18A2 protein
SLC18A2 results in decreased abundance of Dopamine		 CTD PMID:1438304 PMID:7912402 PMID:10499361 PMID:15475732 PMID:18533268 More... NCBI chr 1:258,413,748...258,449,143
Ensembl chr 1:258,413,959...258,448,325 		JBrowse link
G Slc22a1 solute carrier family 22 member 1 multiple interactions EXP Dopamine affects the reaction [SLC22A1 protein results in increased uptake of Tetraethylammonium] CTD PMID:12440152 NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678 		JBrowse link
G Slc22a16 solute carrier family 22 member 16 multiple interactions ISO Dopamine inhibits the reaction [SLC22A16 protein results in increased uptake of Tetraethylammonium] CTD PMID:15963465 NCBI chr20:43,972,808...44,068,447
Ensembl chr20:43,972,836...44,065,019 		JBrowse link
G Slc22a2 solute carrier family 22 member 2 multiple interactions EXP Dopamine affects the reaction [SLC22A2 protein results in increased uptake of Tetraethylammonium] CTD PMID:12440152 NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268 		JBrowse link
G Slc22a3 solute carrier family 22 member 3 increases uptake
multiple interactions		 ISO
EXP		 SLC22A3 protein results in increased uptake of Dopamine
Dopamine affects the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium]; Dopamine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Dopamine inhibits the reaction [SLC22A3 protein results in increased uptake of Dopamine]		 CTD PMID:9830022 PMID:20858707 NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612 		JBrowse link
G Slc25a14 solute carrier family 25 member 14 multiple interactions
decreases response to substance
increases expression		 ISO Dactinomycin inhibits the reaction [Dopamine results in increased expression of SLC25A14 mRNA]; SLC25A14 protein inhibits the reaction [Dopamine results in increased abundance of Superoxides]
SLC25A14 protein results in decreased susceptibility to Dopamine		 CTD PMID:20600837 NCBI chr  X:127,807,630...127,845,823
Ensembl chr  X:127,807,449...127,845,823 		JBrowse link
G Slc25a5 solute carrier family 25 member 5 increases expression ISO Dopamine results in increased expression of SLC25A5 protein CTD PMID:24675778 NCBI chr  X:116,031,896...116,034,963
Ensembl chr  X:116,031,803...116,034,967 		JBrowse link
G Slc25a6 solute carrier family 25 member 6 increases expression ISO Dopamine results in increased expression of SLC25A6 protein CTD PMID:24675778 NCBI chr18:68,571,222...68,572,461
Ensembl chr18:68,571,300...68,572,199 		JBrowse link
G Slc29a4 solute carrier family 29 member 4 increases uptake ISO SLC29A4 protein results in increased uptake of Dopamine CTD PMID:20858707 NCBI chr12:11,853,540...11,884,660
Ensembl chr12:11,853,540...11,874,834 		JBrowse link
G Slc2a4 solute carrier family 2 member 4 decreases expression EXP Dopamine results in decreased expression of SLC2A4 mRNA CTD PMID:21983523 NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565 		JBrowse link
G Slc39a11 solute carrier family 39, member 11 increases expression EXP Dopamine results in increased expression of SLC39A11 mRNA CTD PMID:21983523 NCBI chr10:98,275,958...98,697,042
Ensembl chr10:98,275,960...98,611,295 		JBrowse link
G Slc41a2 solute carrier family 41 member 2 increases expression EXP Dopamine results in increased expression of SLC41A2 mRNA CTD PMID:21983523 NCBI chr 7:20,383,714...20,491,178
Ensembl chr 7:20,383,757...20,491,166 		JBrowse link
G Slc6a2 solute carrier family 6 member 2 multiple interactions
increases uptake		 ISO Desipramine inhibits the reaction [SLC6A2 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A2 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; SLC6A2 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]
SLC6A2 protein results in increased uptake of Dopamine		 CTD PMID:17234900 PMID:20626558 NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357 		JBrowse link
G Slc6a3 solute carrier family 6 member 3 multiple interactions
increases activity
affects uptake
increases import
decreases import
increases response to substance
increases uptake
affects localization
affects export
affects abundance
increases transport
increases export		 ISO
EXP		 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; 4-fluoroamphetamine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; 4-methylaminorex inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; [Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA; [Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein; [SLC6A3 protein polymorphism affects the susceptibility to 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone] which affects the uptake of Dopamine; [SLC6A3 protein polymorphism affects the susceptibility to Bupropion] which affects the uptake of Dopamine; [SLC6A3 protein polymorphism affects the susceptibility to Citalopram] which affects the uptake of Dopamine; [SLC6A3 protein polymorphism affects the susceptibility to Cocaine] which affects the uptake of Dopamine; [SLC6A3 protein polymorphism affects the susceptibility to Methylphenidate] which affects the uptake of Dopamine; [SNCA protein affects the localization of SLC6A3 protein] which affects the uptake of Dopamine; Amphetamine inhibits the reaction [SLC6A3 protein mutant form results in increased export of Dopamine]; Amphetamine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Benztropine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; bisindolylmaleimide I inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; Bupropion inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA]; Bupropion inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; Bupropion inhibits the reaction [SLC6A3 protein mutant form results in decreased import of Dopamine]; Bupropion inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Bupropion promotes the reaction [SLC6A3 protein results in increased import of Dopamine]; Butyrates inhibits the reaction [Cocaine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]]; Butyrates inhibits the reaction [Mazindol inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]]; Citalopram inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Cocaine inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA]; Cocaine inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; Cocaine inhibits the reaction [Dopamine results in increased activity of SLC6A3 protein]; Cocaine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; decamethrin inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Dextroamphetamine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Fluoxetine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Ibogaine inhibits the reaction [SLC6A3 protein mutant form results in decreased import of Dopamine]; Ibogaine promotes the reaction [SLC6A3 protein results in increased import of Dopamine]; indatraline inhibits the reaction [SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; Ketamine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; LRRK2 mutant form results in increased susceptibility to [Dopamine co-treated with SLC6A3 protein]; Mazindol inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Melitten inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA]; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; Methylphenidate inhibits the reaction [SLC6A3 protein mutant form results in increased export of Dopamine]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Nomifensine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; para-methyl-4-methylaminorex inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Permethrin inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]; Sulpiride inhibits the reaction [Dopamine affects the localization of SLC6A3 protein]; Sulpiride inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; vanoxerine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Wortmannin inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]
SLC6A3 protein polymorphism affects the uptake of Dopamine
SLC6A3 protein results in increased susceptibility to Dopamine
DAT protein results in increased uptake of Dopamine
SLC6A3 protein affects the export of Dopamine
[bisphenol A co-treated with Estradiol] inhibits the reaction [SLC6A3 protein affects the export of Dopamine]; [Cullen corylifolium extract results in decreased activity of SLC6A3 protein] which results in decreased uptake of Dopamine; [Dichlorodiphenyl Dichloroethylene co-treated with Estradiol] promotes the reaction [SLC6A3 protein affects the export of Dopamine]; bisphenol A affects the reaction [SLC6A3 protein affects the export of Dopamine]; Cocaine promotes the reaction [SLC6A3 protein affects the uptake of Dopamine]; Dichlorodiphenyl Dichloroethylene inhibits the reaction [SLC6A3 protein affects the export of Dopamine]; Dieldrin inhibits the reaction [SLC6A3 protein affects the export of Dopamine]; Diethylstilbestrol affects the reaction [SLC6A3 protein affects the export of Dopamine]; Endosulfan inhibits the reaction [SLC6A3 protein affects the export of Dopamine]; Estradiol affects the reaction [SLC6A3 protein affects the export of Dopamine]; Modafinil inhibits the reaction [SLC6A3 protein affects the uptake of Dopamine]; nonylphenol affects the reaction [SLC6A3 protein affects the export of Dopamine]
SLC6A3 protein affects the abundance of Dopamine
[Chlorodiphenyl (54% Chlorine) co-treated with aroclor 1260] inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; [decamethrin results in increased expression of SLC6A3 protein] which results in increased uptake of Dopamine; DDT inhibits the reaction [DAT protein results in increased uptake of Dopamine]; Dichlorodiphenyl Dichloroethylene inhibits the reaction [DAT protein results in increased uptake of Dopamine]; Dichlorodiphenyldichloroethane inhibits the reaction [DAT protein results in increased uptake of Dopamine]; Heptachlor promotes the reaction [SLC6A3 protein results in increased uptake of Dopamine]; SLC6A3 mutant form affects the reaction [Cocaine affects the abundance of and affects the uptake of Dopamine]; SLC6A3 mutant form affects the reaction [Fluoxetine affects the abundance of Dopamine]; SLC6A3 mutant form promotes the reaction [Citalopram results in increased abundance of Dopamine]; SLC6A3 protein affects the reaction [[Cocaine co-treated with Alcohols] results in increased uptake of Dopamine]; SLC6A3 protein affects the reaction [Alcohols results in increased uptake of Dopamine]; SLC6A3 protein affects the reaction [Cocaine results in increased uptake of Dopamine]; SLC6A3 protein affects the reaction [Methamphetamine affects the abundance of Dopamine]; SLC6A3 protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]; vanoxerine inhibits the reaction [SLC6A3 protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]]
SLC6A3 protein results in increased transport of Dopamine		 CTD PMID:9634552 PMID:11165777 PMID:11294980 PMID:11707631 PMID:12112414 More... NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413 		JBrowse link
G Slc6a4 solute carrier family 6 member 4 multiple interactions ISO Citalopram inhibits the reaction [SLC6A4 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A4 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; SLC6A4 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein] CTD PMID:17234900 NCBI chr10:61,824,208...61,858,924
Ensembl chr10:61,826,123...61,858,384 		JBrowse link
G Snca synuclein alpha increases response to substance
decreases abundance
affects uptake
multiple interactions
increases abundance
affects response to substance
affects abundance		 ISO
EXP		 SNCA gene mutant form results in increased susceptibility to Dopamine
SNCA protein results in decreased abundance of Dopamine
SNCA protein affects the uptake of Dopamine
[SNCA protein affects the localization of SLC6A3 protein] which affects the uptake of Dopamine; [SNCA protein co-treated with Dopamine] results in increased expression of HMOX1 protein; [SNCA protein co-treated with Paraquat co-treated with Dopamine] results in increased expression of HMOX1 protein; Dopamine inhibits the reaction [SNCA protein results in decreased abundance of Dopamine]; Dopamine inhibits the reaction [SNCA protein results in decreased abundance of Glutathione]; Dopamine inhibits the reaction [SNCA protein results in increased abundance of Thiobarbituric Acid Reactive Substances]; geraniol inhibits the reaction [SNCA protein results in decreased abundance of Dopamine]; TRAP1 protein inhibits the reaction [SNCA protein affects the abundance of Dopamine]
SNCA protein results in increased abundance of Dopamine
SNCA protein promotes the reaction [Rotenone results in decreased abundance of Dopamine]
SNCA protein mutant form results in decreased abundance of Dopamine
SNCA affects the susceptibility to Dopamine		 CTD PMID:15234109 PMID:17131421 PMID:18622040 PMID:19032594 PMID:19409267 More... NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262 		JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions
affects binding
decreases expression		 EXP
ISO		 [Copper Sulfate co-treated with Dopamine] results in decreased expression of SOD1 mRNA; [Dopamine co-treated with Dicumarol co-treated with Copper Sulfate] results in decreased expression of SOD1 mRNA
Dopamine binds to SOD1 protein mutant form
Dopamine results in decreased expression of SOD1 mRNA		 CTD PMID:11299314 PMID:23612299 NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249 		JBrowse link
G Sod2 superoxide dismutase 2 increases expression
decreases expression
multiple interactions		 EXP [Dopamine results in increased expression of HMOX1 mRNA] which results in increased expression of SOD2 mRNA; Dopamine results in increased expression of SOD2 mRNA
Dopamine results in decreased expression of SOD2 mRNA
[Dopamine co-treated with Dicumarol co-treated with Copper Sulfate] results in decreased expression of SOD2 mRNA		 CTD PMID:10942521 PMID:11299314 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189 		JBrowse link
G Ssbp1 single stranded DNA binding protein 1 increases expression ISO Dopamine results in increased expression of SSBP1 protein CTD PMID:24675778 NCBI chr 4:69,266,024...69,276,135
Ensembl chr 4:69,266,102...69,276,135 		JBrowse link
G Sult1a1 sulfotransferase family 1A member 1 multiple interactions
increases metabolic processing		 ISO
EXP		 Mefenamic Acid inhibits the reaction [SULT1A1 protein results in increased sulfation of Dopamine]
SULT1A1 protein results in increased metabolism of Dopamine		 CTD PMID:10623578 PMID:11181495 NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562 		JBrowse link
G Syn1 synapsin I multiple interactions ISO SYN1 protein affects the reaction [Cocaine results in increased secretion of Dopamine] CTD PMID:16554471 NCBI chr  X:1,172,208...1,227,400
Ensembl chr  X:1,172,208...1,227,396 		JBrowse link
G Syn2 synapsin II multiple interactions ISO SYN2 protein affects the reaction [Cocaine results in increased secretion of Dopamine] CTD PMID:16554471 NCBI chr 4:148,178,846...148,347,010
Ensembl chr 4:148,186,270...148,344,192 		JBrowse link
G Syn3 synapsin III multiple interactions ISO SYN3 protein affects the reaction [Cocaine results in increased secretion of Dopamine] CTD PMID:16554471 NCBI chr 7:16,216,055...17,808,790
Ensembl chr 7:17,376,372...17,808,790 		JBrowse link
G Taar1 trace-amine-associated receptor 1 multiple interactions ISO Citalopram inhibits the reaction [SLC6A4 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; Desipramine inhibits the reaction [SLC6A2 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A2 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A4 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; SLC6A2 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]; SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]; SLC6A4 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein] CTD PMID:17234900 NCBI chr 1:21,517,742...21,518,740
Ensembl chr 1:21,517,258...21,532,084 		JBrowse link
G Tdo2 tryptophan 2,3-dioxygenase multiple interactions EXP [Sulindac results in decreased activity of TDO2 protein] which results in decreased abundance of Dopamine; [Tolmetin results in decreased activity of TDO2 protein] which results in decreased abundance of Dopamine CTD PMID:16952380 NCBI chr 2:167,269,581...167,287,511
Ensembl chr 2:167,269,579...167,287,511 		JBrowse link
G Tfam transcription factor A, mitochondrial decreases abundance ISO TFAM gene mutant form results in decreased abundance of Dopamine CTD PMID:28595911 NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 increases expression
multiple interactions
decreases expression		 EXP Dopamine results in increased expression of TGFB1 mRNA
DRD2 mutant form inhibits the reaction [Dopamine results in decreased expression of TGFB1 protein]; eticlopride inhibits the reaction [Dopamine results in decreased expression of TGFB1 protein]		 CTD PMID:16760913 PMID:25818600 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847 		JBrowse link
G Tgfb2 transforming growth factor, beta 2 increases expression EXP Dopamine results in increased expression of TGFB2 mRNA CTD PMID:16760913 NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405 		JBrowse link
G Th tyrosine hydroxylase increases chemical synthesis
affects abundance
decreases activity
multiple interactions
affects chemical synthesis		 ISO
EXP		 TH protein results in increased chemical synthesis of Dopamine
TH protein affects the abundance of Dopamine
TH affects the abundance of Dopamine
Dopamine results in decreased activity of TH protein
1-phenyl-3-dimethylamino-1,2,3,4-tetrahydronaphthalene analog promotes the reaction [TH protein results in increased chemical synthesis of Dopamine]; [1-phenyl-3-dimethylamino-1,2,3,4-tetrahydronaphthalene analog binds to and results in increased activity of HRH1 protein] promotes the reaction [TH protein results in increased chemical synthesis of Dopamine]; [Clonidine results in decreased activity of and results in decreased expression of TH protein] which results in decreased abundance of Dopamine; [Selenium deficiency results in increased activity of TH protein] which results in increased chemical synthesis of Dopamine; Cocaine promotes the reaction [[DRD2 protein results in increased phosphorylation of TH protein] which results in increased abundance of Dopamine]; dicarbine inhibits the reaction [Dopamine results in decreased activity of TH protein]; Paraquat promotes the reaction [TH protein results in increased chemical synthesis of Dopamine]; Spiperone inhibits the reaction [Cocaine promotes the reaction [[DRD2 protein results in increased phosphorylation of TH protein] which results in increased abundance of Dopamine]]; Sulpiride inhibits the reaction [Dopamine results in decreased activity of TH protein]; Triprolidine inhibits the reaction [1-phenyl-3-dimethylamino-1,2,3,4-tetrahydronaphthalene analog promotes the reaction [TH protein results in increased chemical synthesis of Dopamine]]
TH protein affects the chemical synthesis of Dopamine
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine promotes the reaction [[Clozapine results in increased activity of TH protein] which results in increased metabolism of Dopamine]; [Clozapine results in increased activity of TH protein] which results in increased metabolism of Dopamine; [TH protein affects the abundance of Dopamine] which affects the susceptibility to Methamphetamine; [TH protein affects the chemical synthesis of Dopamine] which affects the susceptibility to Methamphetamine		 CTD PMID:2884129 PMID:8707341 PMID:9822156 PMID:10661506 PMID:10984662 More... NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767 		JBrowse link
G Thbs1 thrombospondin 1 increases expression EXP Dopamine results in increased expression of THBS1 mRNA CTD PMID:21983523 NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440 		JBrowse link
G Timp1 TIMP metallopeptidase inhibitor 1 increases expression EXP Dopamine results in increased expression of TIMP1 mRNA CTD PMID:21983523 NCBI chr  X:1,212,969...1,217,714
Ensembl chr  X:1,212,972...1,217,664 		JBrowse link
G Tlr2 toll-like receptor 2 increases expression EXP Dopamine results in increased expression of TLR2 mRNA CTD PMID:21983523 NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630 		JBrowse link
G Tmem97 transmembrane protein 97 increases expression EXP Dopamine results in increased expression of TMEM97 mRNA CTD PMID:21983523 NCBI chr10:63,438,228...63,447,311
Ensembl chr10:63,438,222...63,589,730 		JBrowse link
G Tnc tenascin C increases expression EXP Dopamine results in increased expression of TNC mRNA CTD PMID:21983523 NCBI chr 5:77,375,851...77,460,712
Ensembl chr 5:77,375,851...77,460,624 		JBrowse link
G Tnf tumor necrosis factor multiple interactions
increases expression
increases uptake		 ISO
EXP		 Dopamine promotes the reaction [TNF protein results in increased expression of F3 mRNA]; TNF protein inhibits the reaction [Methamphetamine results in decreased uptake of Dopamine]; TNF protein inhibits the reaction [Methamphetamine results in increased secretion of Dopamine]
vanoxerine inhibits the reaction [Dopamine analog results in increased expression of TNF protein]
Dopamine results in increased expression of TNF protein
Bucladesine inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; Colforsin inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]; DRD2 mutant form inhibits the reaction [Dopamine results in increased expression of TNF protein]; eticlopride inhibits the reaction [Dopamine results in increased expression of TNF protein]; ICI 118551 inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; Metoprolol inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; Propranolol inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]
TNF protein results in increased uptake of Dopamine		 CTD PMID:14999072 PMID:15081246 PMID:20118172 PMID:25818600 PMID:27026709 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Tnfsf10 TNF superfamily member 10 decreases expression EXP Dopamine results in decreased expression of TNFSF10 mRNA CTD PMID:21983523 NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135 		JBrowse link
G Tp53 tumor protein p53 multiple interactions
increases expression		 ISO [Dopamine results in increased expression of HIF1A protein] which results in increased expression of and results in increased phosphorylation of TP53 protein
[Dopamine results in increased expression of HIF1A protein] which results in increased expression of TP53 protein		 CTD PMID:19410601 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524 		JBrowse link
G Tpm4 tropomyosin 4 increases expression EXP Dopamine results in increased expression of TPM4 mRNA CTD PMID:21983523 NCBI chr16:17,684,415...17,698,456
Ensembl chr16:17,683,195...17,705,984 		JBrowse link
G Trap1 TNF receptor-associated protein 1 multiple interactions ISO TRAP1 protein inhibits the reaction [SNCA protein affects the abundance of Dopamine] CTD PMID:22319455 NCBI chr10:11,464,882...11,498,931
Ensembl chr10:11,464,821...11,498,981 		JBrowse link
G Tubb4b tubulin, beta 4B class IVb increases expression EXP Dopamine results in increased expression of TUBB4B mRNA CTD PMID:21983523 NCBI chr 3:8,037,838...8,040,294
Ensembl chr 3:8,037,799...8,040,296 		JBrowse link
G Tubb5 tubulin, beta 5 class I increases expression
decreases expression		 EXP
ISO		 Dopamine results in increased expression of TUBB5 mRNA
Dopamine results in decreased expression of TUBB protein		 CTD PMID:21983523 PMID:24675778 NCBI chr20:2,912,779...2,916,928
Ensembl chr20:2,912,778...2,916,940 		JBrowse link
G Tubb6 tubulin, beta 6 class V increases expression EXP Dopamine results in increased expression of TUBB6 mRNA CTD PMID:21983523 NCBI chr18:60,943,394...60,953,031
Ensembl chr18:60,943,375...60,954,418 		JBrowse link
G Tufm Tu translation elongation factor, mitochondrial increases expression ISO Dopamine results in increased expression of TUFM protein CTD PMID:24675778 NCBI chr 1:181,073,788...181,077,395
Ensembl chr 1:181,073,788...181,077,395 		JBrowse link
G Ube2l3 ubiquitin-conjugating enzyme E2L 3 increases expression EXP Dopamine results in increased expression of UBE2L3 mRNA CTD PMID:21983523 NCBI chr11:83,797,722...83,838,862
Ensembl chr11:83,797,722...83,838,862 		JBrowse link
G Vcan versican increases expression EXP Dopamine results in increased expression of VCAN mRNA CTD PMID:21983523 NCBI chr 2:20,761,718...20,860,637
Ensembl chr 2:20,761,718...20,860,637 		JBrowse link
G Vdac1 voltage-dependent anion channel 1 increases expression ISO Dopamine results in increased expression of VDAC1 protein CTD PMID:24675778 NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640 		JBrowse link
G Vdac2 voltage-dependent anion channel 2 affects expression ISO Dopamine affects the expression of VDAC2 protein CTD PMID:24675778 NCBI chr15:2,462,877...2,476,802
Ensembl chr15:2,463,056...2,476,553 		JBrowse link
G Vdr vitamin D receptor increases abundance ISO VDR protein results in increased abundance of Dopamine CTD PMID:27450565 NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677 		JBrowse link
G Vegfa vascular endothelial growth factor A decreases expression
multiple interactions		 EXP Dopamine results in decreased expression of VEGFA mRNA; Dopamine results in decreased expression of VEGFA protein
DRD2 mutant form inhibits the reaction [Dopamine results in decreased expression of VEGFA protein]; eticlopride inhibits the reaction [Dopamine results in decreased expression of VEGFA mRNA]; eticlopride inhibits the reaction [Dopamine results in decreased expression of VEGFA protein]		 CTD PMID:25818600 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641 		JBrowse link
3-methoxytyramine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Taar1 trace-amine-associated receptor 1 increases activity
multiple interactions		 ISO 3-methoxytyramine results in increased activity of TAAR1 protein
[3-methoxytyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP		 CTD PMID:19725810 NCBI chr 1:21,517,742...21,518,740
Ensembl chr 1:21,517,258...21,532,084 		JBrowse link
G Vdr vitamin D receptor multiple interactions
increases abundance		 ISO Calcitriol promotes the reaction [VDR protein results in increased abundance of 3-methoxytyramine] CTD PMID:27450565 NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677 		JBrowse link
4-methoxytyramine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Taar1 trace-amine-associated receptor 1 increases activity
multiple interactions		 ISO 3-hydroxy-4-methoxyphenethylamine results in increased activity of TAAR1 protein
[3-hydroxy-4-methoxyphenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP		 CTD PMID:19725810 NCBI chr 1:21,517,742...21,518,740
Ensembl chr 1:21,517,258...21,532,084 		JBrowse link
N-acetyldopamine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Mthfs methenyltetrahydrofolate synthetase affects binding ISO N-acetyldopamine binds to MTHFS protein CTD PMID:17055997 NCBI chr 8:89,729,498...89,801,998
Ensembl chr 8:89,729,508...89,799,089 		JBrowse link
N-oleoyldopamine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cnr1 cannabinoid receptor 1 multiple interactions EXP N-oleoyldopamine binds to and results in increased activity of CNR1 protein CTD PMID:12569099 NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099 		JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions ISO N-oleoyldopamine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] CTD PMID:27936102 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO N-oleoyldopamine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] CTD PMID:27936102 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847 		JBrowse link
G Trpv1 transient receptor potential cation channel, subfamily V, member 1 multiple interactions
increases activity		 ISO
EXP		 3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [N-oleoyldopamine promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; [N-oleoyldopamine results in increased activity of TRPV1 protein] which results in increased uptake of Calcium; iodoresiniferatoxin inhibits the reaction [[N-oleoyldopamine results in increased activity of TRPV1 protein] which results in increased uptake of Calcium]; iodoresiniferatoxin inhibits the reaction [N-oleoyldopamine results in increased activity of TRPV1 protein] CTD PMID:12569099 PMID:15615864 NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513 		JBrowse link
N-palmitoyl dopamine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Col1a1 collagen type I alpha 1 chain multiple interactions ISO N-palmitoyl dopamine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] CTD PMID:27936102 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO N-palmitoyl dopamine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] CTD PMID:27936102 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847 		JBrowse link
oxidopamine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc8 ATP binding cassette subfamily C member 8 increases expression EXP Oxidopamine results in increased expression of ABCC8 mRNA; Oxidopamine results in increased expression of ABCC8 protein CTD PMID:15857625 NCBI chr 1:96,598,568...96,679,563
Ensembl chr 1:96,598,647...96,679,510 		JBrowse link
G Abcc9 ATP binding cassette subfamily C member 9 increases expression EXP Oxidopamine results in increased expression of ABCC9 mRNA; Oxidopamine results in increased expression of ABCC9 protein CTD PMID:15857625 NCBI chr 4:175,531,854...175,655,849
Ensembl chr 4:175,532,547...175,655,356 		JBrowse link
G Aco1 aconitase 1 increases expression
affects response to substance
multiple interactions		 ISO Oxidopamine results in increased expression of ACO1 mRNA
ACO1 protein affects the susceptibility to Oxidopamine
[ACO1 protein affects the susceptibility to Oxidopamine] which results in decreased expression of HEPH mRNA; Oxidopamine promotes the reaction [ACO1 protein results in decreased expression of SLC40A1 mRNA]		 CTD PMID:19913091 NCBI chr 5:55,259,841...55,315,872
Ensembl chr 5:55,259,827...55,316,391 		JBrowse link
G Adora2a adenosine A2a receptor multiple interactions EXP 8-(3-chlorostyryl)caffeine inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of ADORA2A protein]; [Oxidopamine co-treated with Levodopa] results in increased expression of ADORA2A mRNA; [Oxidopamine co-treated with Levodopa] results in increased expression of ADORA2A protein CTD PMID:15065221 PMID:21195062 NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386 		JBrowse link
G Ager advanced glycosylation end product-specific receptor affects expression
affects binding		 EXP Oxidopamine affects the expression of AGER protein
Oxidopamine binds to AGER protein		 CTD PMID:26902637 NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078 		JBrowse link
G Aifm1 apoptosis inducing factor, mitochondria associated 1 multiple interactions
affects localization
increases expression		 ISO
EXP		 alpha-iso-cubebenol inhibits the reaction [Oxidopamine affects the localization of AIFM1 protein]; Selegiline inhibits the reaction [Oxidopamine affects the localization of AIFM1 protein]
Oxidopamine results in increased expression of AIFM1 protein		 CTD PMID:12880480 PMID:24997245 PMID:31022188 NCBI chr  X:127,650,223...127,689,356
Ensembl chr  X:127,650,226...127,689,256 		JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 increases expression ISO Oxidopamine results in increased expression of AKR1C3 mRNA; Oxidopamine results in increased expression of AKR1C3 protein CTD PMID:33486071 NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
decreases phosphorylation
affects phosphorylation		 EXP
ISO		 Clenbuterol inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT1 protein]; Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT1 protein]; Dobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT1 protein]; Oxidopamine results in increased phosphorylation of and results in increased activity of AKT1 protein
Oxidopamine affects the phosphorylation of AKT1 protein
2-chloro-5-hydroxyphenylglycine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of AKT1 protein]; 2-chloro-5-hydroxyphenylglycine affects the reaction [Oxidopamine affects the phosphorylation of AKT1 protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of AKT1 protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [Oxidopamine affects the phosphorylation of AKT1 protein]; [GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of AKT1 protein		 CTD PMID:16339297 PMID:21397656 PMID:33571554 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Akt2 AKT serine/threonine kinase 2 multiple interactions
decreases phosphorylation		 EXP Clenbuterol inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT2 protein]; Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT2 protein]; Dobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT2 protein] CTD PMID:16339297 NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817 		JBrowse link
G Akt3 AKT serine/threonine kinase 3 multiple interactions
decreases phosphorylation		 EXP Clenbuterol inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT3 protein]; Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT3 protein]; Dobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT3 protein] CTD PMID:16339297 NCBI chr13:88,943,708...89,225,831
Ensembl chr13:88,946,091...89,225,708 		JBrowse link
G Apod apolipoprotein D multiple interactions
decreases expression		 ISO Celecoxib inhibits the reaction [Oxidopamine results in decreased expression of APOD mRNA] CTD PMID:33160981 NCBI chr11:69,431,261...69,452,306
Ensembl chr11:69,431,260...69,452,305 		JBrowse link
G Atf4 activating transcription factor 4 increases expression
multiple interactions		 EXP Oxidopamine results in increased expression of ATF4 mRNA; Oxidopamine results in increased expression of ATF4 protein
Resveratrol inhibits the reaction [Oxidopamine results in increased expression of ATF4 protein]		 CTD PMID:12486162 PMID:34302886 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446 		JBrowse link
G Atxn2 ataxin 2 multiple interactions
increases expression		 EXP isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of ATXN2 mRNA]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of ATXN2 mRNA]; Rutin inhibits the reaction [Oxidopamine results in increased expression of ATXN2 mRNA] CTD PMID:25129099 NCBI chr12:34,754,132...34,851,175
Ensembl chr12:34,754,137...34,851,479 		JBrowse link
G Atxn3 ataxin 3 multiple interactions
increases expression		 EXP isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of ATXN3 mRNA]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of ATXN3 mRNA]; Rutin inhibits the reaction [Oxidopamine results in increased expression of ATXN3 mRNA] CTD PMID:25129099 NCBI chr 6:121,072,228...121,107,902
Ensembl chr 6:121,074,448...121,107,902 		JBrowse link
G Avpr2 arginine vasopressin receptor 2 increases expression EXP Oxidopamine results in increased expression of AVPR2 mRNA CTD PMID:15303306 NCBI chr  X:151,633,501...151,636,155
Ensembl chr  X:151,633,522...151,635,989 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator affects localization
increases expression
multiple interactions		 ISO
EXP		 Oxidopamine affects the localization of BAX protein
Oxidopamine results in increased expression of BAX protein
5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato iron(III) chloride inhibits the reaction [Oxidopamine results in increased expression of BAX protein]; Resveratrol inhibits the reaction [Oxidopamine results in increased expression of BAX protein]; Tea inhibits the reaction [Oxidopamine results in increased expression of BAX protein]
tricetin inhibits the reaction [Oxidopamine results in increased expression of BAX mRNA]; tricetin inhibits the reaction [Oxidopamine results in increased expression of BAX protein]; Valproic Acid inhibits the reaction [Oxidopamine results in increased expression of BAX protein]
Oxidopamine results in increased expression of BAX mRNA; Oxidopamine results in increased expression of BAX protein		 CTD PMID:16480889 PMID:21397656 PMID:22821850 PMID:28802652 PMID:31176653 More... NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases expression		 ISO
EXP		 PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]]; pyrazolanthrone inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]; salvin inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]; SB 203580 inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]; tricetin inhibits the reaction [Oxidopamine results in decreased expression of BCL2 mRNA]; tricetin inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]
Oxidopamine results in decreased expression of BCL2 mRNA; Oxidopamine results in decreased expression of BCL2 protein
5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato iron(III) chloride inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]; salvin inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]; Tea inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]
[2-chloro-5-hydroxyphenylglycine co-treated with Oxidopamine] results in decreased expression of BCL2 protein; [6-methyl-2-(phenylethynyl)pyridine co-treated with Oxidopamine] results in decreased expression of BCL2 protein		 CTD PMID:16480889 PMID:21397656 PMID:25446857 PMID:28802652 PMID:30707903 More... NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Bdnf brain-derived neurotrophic factor decreases expression
multiple interactions		 ISO Oxidopamine results in decreased expression of BDNF protein
chrysin inhibits the reaction [Oxidopamine results in decreased expression of BDNF protein]		 CTD PMID:29054324 NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615 		JBrowse link
G Calr calreticulin increases expression EXP Oxidopamine results in increased expression of CALR mRNA CTD PMID:12486162 NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414 		JBrowse link
G Casp1 caspase 1 increases expression
multiple interactions		 EXP Oxidopamine results in increased expression of CASP1 mRNA
Levodopa inhibits the reaction [Oxidopamine results in increased expression of CASP1 mRNA]		 CTD PMID:25129099 NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383 		JBrowse link
G Casp12 caspase 12 increases cleavage
multiple interactions		 EXP Oxidopamine results in increased cleavage of CASP12 protein
Resveratrol inhibits the reaction [Oxidopamine results in increased cleavage of CASP12 protein]		 CTD PMID:34302886 NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037 		JBrowse link
G Casp3 caspase 3 increases activity
increases cleavage
multiple interactions
increases expression
affects activity		 ISO
EXP		 Oxidopamine results in increased activity of CASP3 protein
Oxidopamine results in increased cleavage of CASP3 protein
Caffeine inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; ginsenoside Rb1 inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; GSTP1 mutant form inhibits the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; MIR107 mRNA affects the reaction [Oxidopamine affects the activity of CASP3 protein]; OPA1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; Oxidopamine results in increased expression of and results in increased activity of CASP3 protein; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; pinostilbene inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; Plant Extracts inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; puag-haad inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]; Resveratrol inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]; sulforaphane inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; tricetin inhibits the reaction [Oxidopamine results in increased expression of and results in increased activity of CASP3 protein]; Valproic Acid inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]
3-methyladenine inhibits the reaction [Oxidopamine results in increased expression of CASP3 protein modified form]; 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato iron(III) chloride inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; Emodin inhibits the reaction [Oxidopamine results in decreased expression of and results in increased cleavage of CASP3 protein]; Emodin inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of CASP3 mRNA]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; MDL 201053 inhibits the reaction [Oxidopamine results in increased expression of CASP3 protein modified form]; MIR107 mRNA affects the reaction [Oxidopamine affects the activity of CASP3 protein]; Oxidopamine results in decreased expression of and results in increased cleavage of CASP3 protein; Resveratrol inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]; Rutin inhibits the reaction [Oxidopamine results in increased expression of CASP3 mRNA]; salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]
Oxidopamine results in increased expression of CASP3 mRNA; Oxidopamine results in increased expression of CASP3 protein modified form		 CTD PMID:18201823 PMID:18675900 PMID:19443200 PMID:19780897 PMID:19781563 More... NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp7 caspase 7 multiple interactions
increases expression
increases cleavage		 EXP
ISO		 Levodopa inhibits the reaction [Oxidopamine results in increased expression of CASP7 mRNA]; Rutin inhibits the reaction [Oxidopamine results in increased expression of CASP7 mRNA]
Oxidopamine results in increased cleavage of CASP7 protein
Valproic Acid inhibits the reaction [Oxidopamine results in increased cleavage of CASP7 protein]		 CTD PMID:25129099 PMID:32167238 NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729 		JBrowse link
G Casp9 caspase 9 increases activity
multiple interactions
increases cleavage		 ISO
EXP		 Oxidopamine results in increased activity of CASP9 protein
sulforaphane inhibits the reaction [Oxidopamine results in increased activity of CASP9 protein]; Valproic Acid inhibits the reaction [Oxidopamine results in increased cleavage of CASP9 protein]		 CTD PMID:19780897 PMID:19781563 PMID:21846476 PMID:32167238 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626 		JBrowse link
G Cat catalase decreases activity
multiple interactions		 EXP Oxidopamine results in decreased activity of CAT protein
Tea inhibits the reaction [Oxidopamine results in decreased activity of CAT protein]		 CTD PMID:16480889 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478 		JBrowse link
G Cd2ap CD2-associated protein increases expression ISO Oxidopamine results in increased expression of CD2AP mRNA CTD PMID:18535749 NCBI chr 9:18,086,744...18,182,744
Ensembl chr 9:18,086,984...18,182,199 		JBrowse link
G Cdk5 cyclin-dependent kinase 5 multiple interactions EXP [Oxidopamine co-treated with Levodopa] results in increased expression of CDK5 protein CTD PMID:17188499 NCBI chr 4:10,754,682...10,760,110
Ensembl chr 4:10,754,687...10,760,112 		JBrowse link
G Cebpb CCAAT/enhancer binding protein beta increases expression EXP Oxidopamine results in increased expression of CEBPB mRNA CTD PMID:12486162 NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473 		JBrowse link
G Cnr1 cannabinoid receptor 1 affects response to substance ISO CNR1 affects the susceptibility to Oxidopamine CTD PMID:19419794 NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099 		JBrowse link
G Comt catechol-O-methyltransferase increases methylation ISO COMT protein results in increased methylation of Oxidopamine CTD PMID:11160877 NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642 		JBrowse link
G Ctsd cathepsin D multiple interactions
decreases expression		 ISO Celecoxib inhibits the reaction [Oxidopamine results in decreased expression of CTSD mRNA] CTD PMID:33160981 NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488 		JBrowse link
G Cybb cytochrome b-245 beta chain multiple interactions
increases expression		 ISO N-(4-O-glycerol-3-methoxybenzyl)nonivamide inhibits the reaction [Oxidopamine results in increased expression of CYBB protein] CTD PMID:17855475 NCBI chr  X:13,358,101...13,392,570
Ensembl chr  X:13,359,430...13,392,586 		JBrowse link
G Cycs cytochrome c, somatic increases expression EXP Oxidopamine results in increased expression of CYCS protein CTD PMID:31022188 NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054 		JBrowse link
G Ddc dopa decarboxylase decreases expression
multiple interactions		 EXP Oxidopamine results in decreased expression of DDC protein
Levodopa inhibits the reaction [Oxidopamine results in decreased expression of DDC protein]		 CTD PMID:20232137 NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 increases expression
multiple interactions		 EXP
ISO		 Oxidopamine results in increased expression of DDIT3 mRNA; Oxidopamine results in increased expression of DDIT3 protein
Resveratrol inhibits the reaction [Oxidopamine results in increased expression of DDIT3 protein]; sodium bisulfide inhibits the reaction [Oxidopamine results in increased expression of DDIT3 protein]		 CTD PMID:12486162 PMID:32870474 PMID:33961902 PMID:34302886 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Dlg1 discs large MAGUK scaffold protein 1 affects localization
multiple interactions
decreases expression		 EXP Oxidopamine affects the localization of DLG1 protein
[Oxidopamine co-treated with Levodopa] results in increased expression of DLG1 mRNA; [Oxidopamine co-treated with Levodopa] results in increased expression of DLG1 protein
Oxidopamine results in decreased expression of DLG1 protein		 CTD PMID:15703272 NCBI chr11:68,911,883...69,103,230
Ensembl chr11:68,911,883...69,102,689 		JBrowse link
G Dlg4 discs large MAGUK scaffold protein 4 multiple interactions
affects localization
decreases expression		 EXP [Oxidopamine co-treated with Levodopa] results in increased expression of DLG4 mRNA; [Oxidopamine co-treated with Levodopa] results in increased expression of DLG4 protein; Resveratrol inhibits the reaction [Oxidopamine results in decreased expression of DLG4 protein]
Oxidopamine affects the localization of DLG4 protein
Oxidopamine results in decreased expression of DLG4 mRNA; Oxidopamine results in decreased expression of DLG4 protein		 CTD PMID:15703272 PMID:34302886 NCBI chr10:54,740,700...54,769,097
Ensembl chr10:54,739,470...54,767,153 		JBrowse link
G Dnaja2 DnaJ heat shock protein family (Hsp40) member A2 increases expression EXP Oxidopamine results in increased expression of DNAJA2 mRNA CTD PMID:12486162 NCBI chr19:21,497,792...21,516,904
Ensembl chr19:21,497,729...21,516,901 		JBrowse link
G Dnaja3 DnaJ heat shock protein family (Hsp40) member A3 increases degradation
decreases expression		 EXP
ISO		 Oxidopamine results in increased degradation of DNAJA3 protein
Oxidopamine results in decreased expression of DNAJA3 protein		 CTD PMID:22016808 NCBI chr10:10,854,732...10,880,171
Ensembl chr10:10,854,732...10,880,161 		JBrowse link
G Dnm1l dynamin 1-like affects localization
multiple interactions
increases expression		 ISO Oxidopamine affects the localization of DNM1L protein
3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone inhibits the reaction [Oxidopamine affects the localization of DNM1L protein]
Oxidopamine results in increased expression of DNM1L protein		 CTD PMID:22821850 PMID:31705926 NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482 		JBrowse link
G Drd1 dopamine receptor D1 multiple interactions
decreases expression
increases expression		 EXP [Levodopa co-treated with Oxidopamine] results in increased expression of DRD1 mRNA; [Oxidopamine co-treated with levodopa methyl ester] promotes the reaction [Benserazide results in increased expression of DRD1 protein]; Levodopa inhibits the reaction [Oxidopamine results in decreased expression of DRD1 protein]
Oxidopamine results in decreased expression of DRD1 mRNA; Oxidopamine results in decreased expression of DRD1 protein
Oxidopamine results in increased expression of DRD1 protein		 CTD PMID:16365282 PMID:18707801 PMID:19118628 PMID:19399396 NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002 		JBrowse link
G Drd2 dopamine receptor D2 multiple interactions
increases expression		 EXP [Oxidopamine co-treated with levodopa methyl ester] inhibits the reaction [Benserazide results in increased expression of DRD2 protein]; Dopamine promotes the reaction [Oxidopamine binds to DRD2 protein]; Tea inhibits the reaction [Dopamine promotes the reaction [Oxidopamine binds to DRD2 protein]]
Oxidopamine results in increased expression of DRD2 mRNA; Oxidopamine results in increased expression of DRD2 protein		 CTD PMID:16480889 PMID:19118628 PMID:19399396 NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875 		JBrowse link
G Drd3 dopamine receptor D3 multiple interactions
decreases expression		 EXP [Levodopa co-treated with Oxidopamine] results in increased expression of DRD3 mRNA; [Levodopa co-treated with Oxidopamine] results in increased expression of DRD3 protein; Oxidopamine inhibits the reaction [7-hydroxy-2-N,N-dipropylaminotetralin binds to DRD3 protein]
Oxidopamine results in decreased expression of DRD3 mRNA		 CTD PMID:7878047 PMID:17241287 PMID:19118628 NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596 		JBrowse link
G Drd4 dopamine receptor D4 increases expression EXP Oxidopamine results in increased expression of DRD4 mRNA CTD PMID:15303306 NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553 		JBrowse link
G Egf epidermal growth factor decreases activity EXP Oxidopamine results in decreased activity of EGF protein CTD PMID:9324159 NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064 		JBrowse link
G Egln1 egl-9 family hypoxia-inducible factor 1 multiple interactions
increases expression		 EXP isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of EGLN1 mRNA]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of EGLN1 mRNA]; Rutin inhibits the reaction [Oxidopamine results in increased expression of EGLN1 mRNA] CTD PMID:25129099 NCBI chr19:52,867,900...52,907,308
Ensembl chr19:52,869,486...52,907,777 		JBrowse link
G Egr1 early growth response 1 multiple interactions EXP [Oxidopamine co-treated with Levodopa] results in increased expression of EGR1 mRNA CTD PMID:9890435 NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766 		JBrowse link
G Eif2a eukaryotic translation initiation factor 2A multiple interactions EXP Oxidopamine results in increased phosphorylation of and results in increased activity of EIF2A protein CTD PMID:12486162 NCBI chr 2:142,761,303...142,794,767
Ensembl chr 2:142,761,416...142,795,068 		JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 affects response to substance
multiple interactions		 ISO
EXP		 EIF2AK3 protein affects the susceptibility to Oxidopamine
Oxidopamine results in increased phosphorylation of and results in increased activity of EIF2AK3 protein		 CTD PMID:12486162 NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911 		JBrowse link
G En1 engrailed homeobox 1 multiple interactions ISO [EN1 protein co-treated with EN2 protein] results in decreased susceptibility to Oxidopamine CTD PMID:21892157 NCBI chr13:31,750,892...31,756,477
Ensembl chr13:31,751,545...31,755,943 		JBrowse link
G En2 engrailed homeobox 2 multiple interactions ISO [EN1 protein co-treated with EN2 protein] results in decreased susceptibility to Oxidopamine CTD PMID:21892157 NCBI chr 4:7,221,096...7,226,943
Ensembl chr 4:7,221,096...7,226,943 		JBrowse link
G Ephb1 Eph receptor B1 decreases expression ISO Oxidopamine results in decreased expression of EPHB1 protein CTD PMID:11146119 NCBI chr 8:102,507,549...102,944,839
Ensembl chr 8:102,507,549...102,944,839 		JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 multiple interactions EXP Oxidopamine results in increased phosphorylation of and results in increased activity of ERN1 protein CTD PMID:12486162 NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029 		JBrowse link
G Esr1 estrogen receptor 1 increases expression EXP Oxidopamine results in increased expression of ESR1 mRNA CTD PMID:12486162 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002 		JBrowse link
G Fgf10 fibroblast growth factor 10 increases expression EXP Oxidopamine results in increased expression of FGF10 mRNA CTD PMID:15303306 NCBI chr 2:50,801,171...50,878,218
Ensembl chr 2:50,800,992...50,876,866 		JBrowse link
G Fibin fin bud initiation factor homolog increases expression ISO Oxidopamine results in increased expression of FIBIN mRNA CTD PMID:32870474 NCBI chr 3:96,942,405...96,944,676
Ensembl chr 3:96,942,406...96,944,676 		JBrowse link
G Fis1 fission, mitochondrial 1 increases expression
multiple interactions		 ISO Oxidopamine results in increased expression of FIS1 protein
salvin inhibits the reaction [Oxidopamine results in increased expression of FIS1 protein]		 CTD PMID:31705926 NCBI chr12:19,708,560...19,723,392
Ensembl chr12:19,708,558...19,723,377 		JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions
decreases expression		 EXP [Levodopa co-treated with Oxidopamine] results in increased expression of FOS protein; [Oxidopamine co-treated with Levodopa] results in increased expression of FOS mRNA; [Oxidopamine co-treated with Levodopa] results in increased expression of FOS protein; GDNF protein inhibits the reaction [Oxidopamine inhibits the reaction [Amphetamine results in increased expression of FOS protein]]; Oxidopamine inhibits the reaction [Amphetamine results in increased expression of FOS protein]
Oxidopamine results in decreased expression of FOS protein		 CTD PMID:11031079 PMID:14526427 PMID:16325000 PMID:16706847 PMID:17329435 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036 		JBrowse link
G Fosb FosB proto-oncogene, AP-1 transcription factor subunit multiple interactions
increases expression		 ISO
EXP		 [Levodopa co-treated with Oxidopamine] results in increased expression of FOSB protein; [Oxidopamine co-treated with Levodopa] results in increased expression of FOSB protein
Oxidopamine results in increased expression of FOSB protein
6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [[Levodopa co-treated with Oxidopamine] results in increased expression of FOSB protein]; [Levodopa co-treated with Oxidopamine] results in increased expression of FOSB protein; [Oxidopamine co-treated with Levodopa] results in increased expression of FOSB protein; [TH co-treated with GCH1] inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of FOSB protein]; Levodopa promotes the reaction [Oxidopamine results in increased expression of FOSB protein]		 CTD PMID:12127155 PMID:15207268 PMID:15659429 PMID:16095907 PMID:16139809 More... NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465 		JBrowse link
G Gad1 glutamate decarboxylase 1 multiple interactions
increases expression		 EXP 6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [Levodopa promotes the reaction [Oxidopamine results in increased expression of GAD1 mRNA]]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of GAD1 mRNA]; Levodopa promotes the reaction [Oxidopamine results in increased expression of GAD1 mRNA] CTD PMID:12077209 PMID:15044549 PMID:15610165 PMID:17241287 PMID:19660528 NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333 		JBrowse link
G Gad2 glutamate decarboxylase 2 multiple interactions
increases expression		 EXP Levodopa promotes the reaction [Oxidopamine results in increased expression of GAD2 mRNA] CTD PMID:19660528 NCBI chr17:84,763,630...84,826,155
Ensembl chr17:84,763,628...84,826,155 		JBrowse link
G Galr2 galanin receptor 2 decreases expression
increases expression		 EXP Oxidopamine results in decreased expression of GALR2 mRNA
Oxidopamine results in increased expression of GALR2 mRNA		 CTD PMID:15303306 PMID:15518916 NCBI chr10:101,513,689...101,517,176
Ensembl chr10:101,514,471...101,517,176 		JBrowse link
G Gch1 GTP cyclohydrolase 1 multiple interactions EXP [TH co-treated with GCH1] inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of FOSB protein]; [TH co-treated with GCH1] inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of PDYN mRNA]; [TH co-treated with GCH1] inhibits the reaction [Levodopa promotes the reaction [Oxidopamine results in increased expression of PENK mRNA]] CTD PMID:15659429 NCBI chr15:20,404,267...20,437,727
Ensembl chr15:20,402,527...20,437,698 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit decreases expression
multiple interactions
increases expression		 ISO
EXP		 Oxidopamine results in decreased expression of GCLC protein
salvin inhibits the reaction [Oxidopamine results in decreased expression of GCLC protein]
Oxidopamine results in increased expression of GCLC mRNA; Oxidopamine results in increased expression of GCLC protein		 CTD PMID:21397656 PMID:25446857 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544 		JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit decreases expression
multiple interactions
increases expression		 ISO
EXP		 Oxidopamine results in decreased expression of GCLM protein
AL 8810 inhibits the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of GCLM mRNA]]; fluprostenol promotes the reaction [Oxidopamine results in increased expression of GCLM mRNA]; PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of GCLM mRNA]]; salvin inhibits the reaction [Oxidopamine results in decreased expression of GCLM protein]		 CTD PMID:25446857 PMID:33486071 NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535 		JBrowse link
G Gdnf glial cell derived neurotrophic factor affects response to substance
multiple interactions
decreases expression		 ISO
EXP		 GDNF protein affects the susceptibility to Oxidopamine
GDNF protein inhibits the reaction [Oxidopamine results in decreased secretion of Dopamine]
GDNF protein affects the susceptibility to [Apomorphine co-treated with Oxidopamine]; GDNF protein affects the susceptibility to [Dextroamphetamine co-treated with Oxidopamine]; GDNF protein affects the susceptibility to [Oxidopamine co-treated with Amphetamine]; GDNF protein affects the susceptibility to [Oxidopamine co-treated with Dextroamphetamine]; GDNF protein inhibits the reaction [Oxidopamine inhibits the reaction [Amphetamine results in increased expression of FOS protein]]
chrysin inhibits the reaction [Oxidopamine results in decreased expression of GDNF protein]		 CTD PMID:11031079 PMID:11312561 PMID:11771942 PMID:12213621 PMID:12429192 More... NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209 		JBrowse link
G Gfap glial fibrillary acidic protein decreases expression
multiple interactions
increases expression		 EXP Oxidopamine results in decreased expression of GFAP protein
Resveratrol inhibits the reaction [Oxidopamine results in increased expression of GFAP protein]; Rosiglitazone promotes the reaction [Oxidopamine results in increased expression of GFAP protein]		 CTD PMID:22842585 PMID:24486959 PMID:34302886 NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589 		JBrowse link
G Gopc golgi associated PDZ and coiled-coil motif containing affects expression
multiple interactions
affects response to substance		 EXP
ISO		 Oxidopamine affects the expression of GOPC protein
2-chloro-5-hydroxyphenylglycine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the expression of TH protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the expression of TH protein]; [GOPC protein affects the susceptibility to Oxidopamine] which affects the expression of TH protein
2-chloro-5-hydroxyphenylglycine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of AKT1 protein]; 2-chloro-5-hydroxyphenylglycine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK1 protein]; 2-chloro-5-hydroxyphenylglycine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK3 protein]; 2-chloro-5-hydroxyphenylglycine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK8 protein]; 2-chloro-5-hydroxyphenylglycine affects the reaction [Oxidopamine affects the expression of GOPC protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of AKT1 protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK1 protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK3 protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK8 protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [Oxidopamine affects the expression of GOPC protein]; [GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of AKT1 protein; [GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK1 protein; [GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK3 protein; [GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK8 protein; GOPC protein affects the reaction [2-chloro-5-hydroxyphenylglycine affects the reaction [Oxidopamine results in increased cleavage of PARP1 protein]]; GOPC protein affects the reaction [6-methyl-2-(phenylethynyl)pyridine promotes the reaction [Oxidopamine results in increased cleavage of PARP1 protein]]; GOPC protein affects the reaction [Oxidopamine results in increased cleavage of PARP1 protein]		 CTD PMID:33571554 NCBI chr20:31,727,617...31,776,904
Ensembl chr20:31,727,620...31,776,903 		JBrowse link
G Gria2 glutamate ionotropic receptor AMPA type subunit 2 decreases expression EXP Oxidopamine results in decreased expression of GRIA2 mRNA CTD PMID:11290405 NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510 		JBrowse link
G Grin1 glutamate ionotropic receptor NMDA type subunit 1 decreases expression
multiple interactions		 EXP Oxidopamine results in decreased expression of GRIN1 mRNA; Oxidopamine results in decreased expression of GRIN1 protein alternative form
Levodopa inhibits the reaction [Oxidopamine results in decreased expression of GRIN1 protein alternative form]		 CTD PMID:15518916 PMID:16365282 NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603 		JBrowse link
G Grin2b glutamate ionotropic receptor NMDA type subunit 2B multiple interactions
decreases expression		 EXP Levodopa inhibits the reaction [Oxidopamine results in decreased expression of GRIN2B protein] CTD PMID:16365282 NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279 		JBrowse link
G Grm1 glutamate metabotropic receptor 1 multiple interactions ISO [benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of GRM1 protein CTD PMID:17596448 NCBI chr 1:5,058,285...5,453,170
Ensembl chr 1:5,058,292...5,453,170 		JBrowse link
G Grm5 glutamate metabotropic receptor 5 affects expression ISO
EXP		 Oxidopamine affects the expression of GRM5 protein CTD PMID:33571554 NCBI chr 1:141,310,069...141,884,980
Ensembl chr 1:141,312,368...141,882,274 		JBrowse link
G Gsr glutathione-disulfide reductase decreases expression
multiple interactions
decreases activity		 ISO
EXP		 Oxidopamine results in decreased expression of GSR protein
salvin inhibits the reaction [Oxidopamine results in decreased expression of GSR protein]
sulforaphane inhibits the reaction [Oxidopamine results in decreased activity of GSR protein]		 CTD PMID:23518299 PMID:25446857 NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661 		JBrowse link
G Gstp1 glutathione S-transferase pi 1 multiple interactions
decreases expression		 ISO
EXP		 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of GSTP1 protein]]; GSTP1 mutant form inhibits the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of GSTP1 protein]]; GSTP1 mutant form inhibits the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; salvin inhibits the reaction [Oxidopamine results in decreased expression of GSTP1 protein] CTD PMID:25271104 NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226 		JBrowse link
G Hax1 HCLS1 associated protein X-1 increases expression ISO Oxidopamine results in increased expression of HAX1 protein CTD PMID:19763263 NCBI chr 2:175,434,242...175,437,926
Ensembl chr 2:175,434,238...175,437,714 		JBrowse link
G Heph hephaestin decreases expression
multiple interactions		 ISO Oxidopamine results in decreased expression of HEPH mRNA; Oxidopamine results in decreased expression of HEPH protein
[ACO1 protein affects the susceptibility to Oxidopamine] which results in decreased expression of HEPH mRNA; [IREB2 protein affects the susceptibility to Oxidopamine] which results in decreased expression of HEPH mRNA		 CTD PMID:19913091 NCBI chr  X:61,151,131...61,402,980
Ensembl chr  X:61,296,345...61,402,980 		JBrowse link
G Herpud1 homocysteine inducible ER protein with ubiquitin like domain 1 increases expression EXP Oxidopamine results in increased expression of HERPUD1 mRNA CTD PMID:12486162 NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424 		JBrowse link
G Hes1 hes family bHLH transcription factor 1 affects expression
multiple interactions		 EXP
ISO		 Oxidopamine affects the expression of HES1 protein
MIR107 mRNA affects the reaction [Oxidopamine affects the expression of HES1 protein]; PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of HES1 protein]]		 CTD PMID:31778666 NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
decreases expression
increases expression		 ISO
EXP		 AL 8810 inhibits the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of HMOX1 mRNA]]; fluprostenol promotes the reaction [Oxidopamine results in increased expression of HMOX1 mRNA]; N-(4-O-glycerol-3-methoxybenzyl)nonivamide inhibits the reaction [Oxidopamine results in decreased expression of HMOX1 protein]; PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of HMOX1 mRNA]]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Oxidopamine results in increased expression of HMOX1 protein]; [5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato iron(III) chloride results in decreased abundance of Peroxynitrous Acid] inhibits the reaction [Oxidopamine results in increased expression of HMOX1 protein]; Acetylcysteine inhibits the reaction [Oxidopamine results in increased expression of HMOX1 protein]; N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [Oxidopamine results in increased expression of HMOX1 protein]; U 0126 inhibits the reaction [Oxidopamine results in increased expression of HMOX1 protein]
Oxidopamine results in increased expression of HMOX1 mRNA; Oxidopamine results in increased expression of HMOX1 protein		 CTD PMID:17676812 PMID:17855475 PMID:21397656 PMID:33486071 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079 		JBrowse link
G Hpgd 15-hydroxyprostaglandin dehydrogenase increases expression ISO Oxidopamine results in increased expression of HPGD mRNA CTD PMID:31247335 NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228 		JBrowse link
G Hsp90ab1 heat shock protein 90 alpha family class B member 1 increases expression EXP Oxidopamine results in increased expression of HSP90AB1 mRNA CTD PMID:12486162 NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488 		JBrowse link
G Hsp90b1 heat shock protein 90 beta family member 1 increases expression EXP Oxidopamine results in increased expression of HSP90B1 mRNA CTD PMID:12486162 NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788 		JBrowse link
G Hspa1l heat shock protein family A (Hsp70) member 1 like increases expression EXP Oxidopamine results in increased expression of HSPA1L mRNA CTD PMID:12486162 NCBI chr20:3,848,843...3,855,571
Ensembl chr20:3,848,843...3,855,571 		JBrowse link
G Hspa4 heat shock protein family A (Hsp70) member 4 increases expression EXP Oxidopamine results in increased expression of HSPA4 mRNA CTD PMID:12486162 NCBI chr10:37,408,025...37,449,080
Ensembl chr10:37,408,025...37,449,001 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 increases expression
multiple interactions		 EXP Oxidopamine results in increased expression of HSPA5 mRNA; Oxidopamine results in increased expression of HSPA5 protein
Resveratrol inhibits the reaction [Oxidopamine results in increased expression of HSPA5 protein]; sodium bisulfide inhibits the reaction [Oxidopamine results in increased expression of HSPA5 protein]		 CTD PMID:12486162 PMID:33961902 PMID:34302886 NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891 		JBrowse link
G Hspa8 heat shock protein family A (Hsp70) member 8 increases expression ISO
EXP		 Oxidopamine results in increased expression of HSPA8 mRNA CTD PMID:12486162 PMID:19763263 NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259 		JBrowse link
G Hspb1 heat shock protein family B (small) member 1 increases expression EXP Oxidopamine results in increased expression of HSPB1 mRNA CTD PMID:12486162 NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743 		JBrowse link
G Hspe1 heat shock protein family E (Hsp10) member 1 increases expression EXP Oxidopamine results in increased expression of HSPE1 mRNA CTD PMID:12486162 NCBI chr 9:56,589,912...56,593,000
Ensembl chr 9:56,589,789...56,593,089 		JBrowse link
G Htr1a 5-hydroxytryptamine receptor 1A decreases expression
multiple interactions		 EXP Oxidopamine results in decreased expression of HTR1A mRNA
stepholidine inhibits the reaction [Oxidopamine results in decreased expression of HTR1A mRNA]		 CTD PMID:18707801 NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442 		JBrowse link
G Htra2 HtrA serine peptidase 2 increases expression ISO Oxidopamine results in increased expression of HTRA2 mRNA; Oxidopamine results in increased expression of HTRA2 protein CTD PMID:19763263 NCBI chr 4:115,556,914...115,560,202
Ensembl chr 4:115,556,916...115,560,095 		JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions EXP Oxidopamine inhibits the reaction [Freund's Adjuvant results in increased expression of ICAM1] CTD PMID:20600813 NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438 		JBrowse link
G Idh3a isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha decreases expression ISO Oxidopamine results in decreased expression of IDH3A mRNA CTD PMID:19763263 NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084 		JBrowse link
G Ifng interferon gamma increases expression
multiple interactions		 ISO Oxidopamine results in increased expression of IFNG protein
chrysin inhibits the reaction [Oxidopamine results in increased expression of IFNG protein]		 CTD PMID:29054324 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375 		JBrowse link
G Il10 interleukin 10 multiple interactions
decreases expression		 ISO chrysin inhibits the reaction [Oxidopamine results in decreased expression of IL10 protein] CTD PMID:29054324 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313 		JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases expression		 ISO
EXP		 chrysin inhibits the reaction [Oxidopamine results in increased expression of IL1B protein]
Resveratrol inhibits the reaction [Oxidopamine results in increased expression of IL1B protein]		 CTD PMID:29054324 PMID:34302886 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Il2 interleukin 2 increases expression ISO Oxidopamine results in increased expression of IL2 protein CTD PMID:29054324 NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566 		JBrowse link
G Il6 interleukin 6 increases expression
multiple interactions		 ISO Oxidopamine results in increased expression of IL6 protein
chrysin inhibits the reaction [Oxidopamine results in increased expression of IL6 protein]		 CTD PMID:29054324 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Ireb2 iron responsive element binding protein 2 increases expression
multiple interactions		 ISO Oxidopamine results in increased expression of IREB2 mRNA
[IREB2 protein affects the susceptibility to Oxidopamine] which results in decreased expression of HEPH mRNA; Oxidopamine promotes the reaction [IREB2 protein results in decreased expression of SLC40A1 mRNA]		 CTD PMID:19913091 NCBI chr 8:55,228,080...55,311,613
Ensembl chr 8:55,228,085...55,311,611 		JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions
increases phosphorylation		 ISO Apomorphine inhibits the reaction [Oxidopamine results in increased phosphorylation of JUN protein]; pinostilbene inhibits the reaction [Oxidopamine results in increased phosphorylation of JUN protein]; puag-haad inhibits the reaction [Oxidopamine results in increased phosphorylation of JUN protein]
Acetylcysteine inhibits the reaction [Oxidopamine promotes the reaction [MAPK8 protein binds to and results in increased phosphorylation of JUN protein]]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Oxidopamine promotes the reaction [MAPK8 protein binds to and results in increased phosphorylation of JUN protein]]; Oxidopamine promotes the reaction [MAPK8 protein binds to and results in increased phosphorylation of JUN protein]		 CTD PMID:10397638 PMID:14599342 PMID:18675900 PMID:19443200 NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656 		JBrowse link
G Junb JunB proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP [Oxidopamine co-treated with Levodopa] results in increased expression of JUNB mRNA; Dizocilpine Maleate inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of JUNB mRNA]; eticlopride affects the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of JUNB mRNA]; Oxidopamine results in increased localization of and results in increased activity of JUNB protein CTD PMID:9890435 PMID:17368433 NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035 		JBrowse link
G Kcnj11 potassium inwardly-rectifying channel, subfamily J, member 11 increases expression EXP Oxidopamine results in increased expression of KCNJ11 mRNA; Oxidopamine results in increased expression of KCNJ11 protein CTD PMID:15857625 NCBI chr 1:96,591,048...96,594,574
Ensembl chr 1:96,591,049...96,594,082 		JBrowse link
G Kcnj8 potassium inwardly-rectifying channel, subfamily J, member 8 increases expression EXP Oxidopamine results in increased expression of KCNJ8 mRNA; Oxidopamine results in increased expression of KCNJ8 protein CTD PMID:15857625 NCBI chr 4:175,508,908...175,515,829
Ensembl chr 4:175,508,912...175,515,603 		JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 affects response to substance ISO KEAP1 mRNA affects the susceptibility to Oxidopamine CTD PMID:16092930 NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862 		JBrowse link
G Lonp1 lon peptidase 1, mitochondrial increases expression EXP Oxidopamine results in increased expression of LONP1 mRNA CTD PMID:12486162 NCBI chr 9:1,447,444...1,459,771
Ensembl chr 9:1,447,447...1,459,771 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta increases expression EXP Oxidopamine results in increased expression of MAP1LC3B protein modified form CTD PMID:28802652 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 increases phosphorylation
multiple interactions
affects phosphorylation		 ISO
EXP		 Oxidopamine results in increased phosphorylation of MAPK1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK1 protein]; AL 8810 inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK1 protein]; alpha-iso-cubebenol inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK1 protein]; fluprostenol promotes the reaction [Oxidopamine results in increased phosphorylation of MAPK1 protein]
2-chloro-5-hydroxyphenylglycine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK1 protein]; 2-chloro-5-hydroxyphenylglycine affects the reaction [Oxidopamine affects the phosphorylation of MAPK1 protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK1 protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [Oxidopamine affects the phosphorylation of MAPK1 protein]; [benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of MAPK1 protein; [GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK1 protein; [Levodopa co-treated with Oxidopamine] results in increased phosphorylation of MAPK1 protein; [Oxidopamine co-treated with Levodopa] results in increased expression of MAPK1 protein; [Oxidopamine co-treated with Levodopa] results in increased phosphorylation of MAPK1 protein; SCH 23390 inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of MAPK1 protein]; SL 327 inhibits the reaction [[benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of MAPK1 protein]; sulforaphane inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK1 protein]
Oxidopamine results in increased phosphorylation of and results in increased activity of MAPK1 protein		 CTD PMID:16139809 PMID:17596448 PMID:19187092 PMID:19520364 PMID:21397656 More... NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation
affects phosphorylation		 ISO
EXP		 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK3 protein]; AL 8810 inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK3 protein]; alpha-iso-cubebenol inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK3 protein]; fluprostenol promotes the reaction [Oxidopamine results in increased phosphorylation of MAPK3 protein]
2-chloro-5-hydroxyphenylglycine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK3 protein]; 2-chloro-5-hydroxyphenylglycine affects the reaction [Oxidopamine affects the phosphorylation of MAPK3 protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK3 protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [Oxidopamine affects the phosphorylation of MAPK3 protein]; [benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of MAPK3 protein; [GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK3 protein; [Levodopa co-treated with Oxidopamine] results in increased phosphorylation of MAPK3 protein; [Oxidopamine co-treated with Levodopa] results in increased expression of MAPK3 protein; [Oxidopamine co-treated with Levodopa] results in increased phosphorylation of MAPK3 protein; SCH 23390 inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of MAPK3 protein]; SL 327 inhibits the reaction [[benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of MAPK3 protein]; sulforaphane inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK3 protein]
Oxidopamine results in increased phosphorylation of and results in increased activity of MAPK3 protein		 CTD PMID:16139809 PMID:17596448 PMID:19187092 PMID:19520364 PMID:21397656 More... NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 increases phosphorylation
multiple interactions		 ISO
EXP		 Oxidopamine results in increased phosphorylation of MAPK8 protein
2-chloro-5-hydroxyphenylglycine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK8 protein]; 2-chloro-5-hydroxyphenylglycine promotes the reaction [Oxidopamine results in increased phosphorylation of MAPK8 protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK8 protein]; 6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK8 protein]; [GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK8 protein; Acetylcysteine inhibits the reaction [Oxidopamine promotes the reaction [MAPK8 protein binds to and results in increased phosphorylation of JUN protein]]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Oxidopamine promotes the reaction [MAPK8 protein binds to and results in increased phosphorylation of JUN protein]]; Oxidopamine promotes the reaction [MAPK8 protein binds to and results in increased phosphorylation of JUN protein]
puag-haad inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK8 protein]; tricetin inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK8 protein]
salvin inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK8 protein]		 CTD PMID:10397638 PMID:18675900 PMID:25446857 PMID:31176653 PMID:33571554 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981 		JBrowse link
G Mapk9 mitogen-activated protein kinase 9 increases phosphorylation
multiple interactions		 ISO
EXP		 Oxidopamine results in increased phosphorylation of MAPK9 protein
salvin inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK9 protein]
puag-haad inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK9 protein]		 CTD PMID:18675900 PMID:25446857 NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178 		JBrowse link
G Mapt microtubule-associated protein tau multiple interactions EXP Oxidopamine results in increased cleavage of and results in decreased phosphorylation of MAPT protein CTD PMID:12686375 NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129 		JBrowse link
G Mfn2 mitofusin 2 multiple interactions
decreases expression		 ISO salvin inhibits the reaction [Oxidopamine results in decreased expression of MFN2 protein] CTD PMID:31705926 NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342 		JBrowse link
G Mir107 microRNA 107 decreases expression
multiple interactions		 ISO
EXP		 Oxidopamine results in decreased expression of MIR107 mRNA
[Oxidopamine affects the reaction [MIR107 mRNA binds to PDCD10 3' UTR]] which affects the expression of PDCD10 mRNA; [Oxidopamine affects the reaction [MIR107 mRNA binds to PDCD10 3' UTR]] which affects the expression of PDCD10 protein; MIR107 mRNA affects the reaction [Oxidopamine affects the activity of CASP3 protein]; MIR107 mRNA affects the reaction [Oxidopamine affects the expression of HES1 protein]; MIR107 mRNA affects the reaction [Oxidopamine affects the expression of NOTCH1 protein]; Oxidopamine affects the reaction [MIR107 mRNA binds to PDCD10 3' UTR]; PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of HES1 protein]]; PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of NOTCH1 protein]]
MIR107 mRNA affects the reaction [Oxidopamine affects the activity of CASP3 protein]; MIR107 mRNA affects the reaction [Oxidopamine affects the expression of HES1 protein]; MIR107 mRNA affects the reaction [Oxidopamine affects the expression of NOTCH1 protein]; PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of HES1 protein]]; PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of NOTCH1 protein]]		 CTD PMID:31778666 NCBI chr 1:232,337,767...232,337,853
Ensembl chr 1:232,337,767...232,337,853 		JBrowse link
G Mitf melanocyte inducing transcription factor multiple interactions ISO [Oxidopamine co-treated with Celecoxib] results in increased expression of MITF mRNA; Oxidopamine promotes the reaction [Celecoxib results in increased expression of MITF mRNA] CTD PMID:33160981 NCBI chr 4:130,409,020...130,621,145
Ensembl chr 4:130,409,217...130,621,145 		JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions
increases expression		 ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Oxidopamine results in increased expression of MMP9 mRNA]; Acetylcysteine inhibits the reaction [Oxidopamine results in increased expression of MMP9 mRNA]; SB 203580 inhibits the reaction [Oxidopamine results in increased expression of MMP9 mRNA] CTD PMID:19962414 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120 		JBrowse link
G Mt1-ps3 metallothionein 1, pseudogene 3 increases expression ISO Oxidopamine results in increased expression of MT1E mRNA CTD PMID:32870474 NCBI chr17:74,786,652...74,787,040
Ensembl chr17:74,786,654...74,787,135 		JBrowse link
G Mt2A metallothionein 2A decreases response to substance
increases expression		 EXP
ISO		 MT2A protein results in decreased susceptibility to Oxidopamine
Oxidopamine results in increased expression of MT2A mRNA		 CTD PMID:14604781 PMID:32870474 NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784 		JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor increases expression EXP Oxidopamine results in increased expression of MYC protein CTD PMID:17368433 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630 		JBrowse link
G Naip6 NLR family, apoptosis inhibitory protein 6 decreases response to substance EXP NAIP protein results in decreased susceptibility to Oxidopamine CTD PMID:11553289 NCBI chr 2:31,507,423...31,559,098
Ensembl chr 2:31,507,424...31,570,542 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions
decreases response to substance
increases activity
increases expression
increases localization
decreases expression
affects localization		 ISO
EXP		 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Oxidopamine affects the localization of NFE2L2 protein]; [2-tert-butylhydroquinone results in increased expression of NFE2L2 protein] which results in decreased susceptibility to Oxidopamine; [linsidomine results in increased expression of NFE2L2 protein] which results in decreased susceptibility to Oxidopamine; AL 8810 inhibits the reaction [Oxidopamine affects the localization of NFE2L2 protein]
NFE2L2 protein results in decreased susceptibility to Oxidopamine
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Oxidopamine results in increased expression of NFE2L2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Oxidopamine results in increased localization of NFE2L2 protein]
Oxidopamine results in increased activity of NFE2L2 protein
Oxidopamine results in increased expression of NFE2L2 mRNA; Oxidopamine results in increased expression of NFE2L2 protein
Oxidopamine results in decreased expression of NFE2L2 protein		 CTD PMID:16092930 PMID:17676812 PMID:21397656 PMID:29057453 PMID:33486071 More... NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Nfkbia NFKB inhibitor alpha decreases expression
increases phosphorylation		 ISO Oxidopamine results in decreased expression of NFKBIA protein
Oxidopamine results in increased phosphorylation of NFKBIA protein		 CTD PMID:20851755 PMID:31247335 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941 		JBrowse link
G Ngf nerve growth factor multiple interactions
decreases expression		 ISO chrysin inhibits the reaction [Oxidopamine results in decreased expression of NGF protein] CTD PMID:29054324 NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452 		JBrowse link
G Nos1 nitric oxide synthase 1 multiple interactions
increases expression		 ISO N-(4-O-glycerol-3-methoxybenzyl)nonivamide inhibits the reaction [Oxidopamine results in increased expression of NOS1 protein] CTD PMID:17855475 NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945 		JBrowse link
G Nos2 nitric oxide synthase 2 increases expression
multiple interactions		 ISO
EXP		 Oxidopamine results in increased expression of NOS2 protein
N-(4-O-glycerol-3-methoxybenzyl)nonivamide inhibits the reaction [Oxidopamine results in increased expression of NOS2 protein]
[Oxidopamine results in increased expression of NOS2 protein] which results in increased secretion of Nitrites		 CTD PMID:17855475 PMID:21397656 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210 		JBrowse link
G Notch1 notch receptor 1 multiple interactions
affects expression		 ISO
EXP		 MIR107 mRNA affects the reaction [Oxidopamine affects the expression of NOTCH1 protein]; PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of NOTCH1 protein]] CTD PMID:31778666 NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531 		JBrowse link
G Npy neuropeptide Y decreases expression
increases expression		 EXP Oxidopamine results in decreased expression of NPY protein
Oxidopamine results in increased expression of NPY mRNA		 CTD PMID:3805164 PMID:9460767 PMID:15303306 NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression
multiple interactions		 EXP
ISO		 Oxidopamine results in increased expression of NQO1 mRNA; Oxidopamine results in increased expression of NQO1 protein
AL 8810 inhibits the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of NQO1 mRNA]]; fluprostenol promotes the reaction [Oxidopamine results in increased expression of NQO1 mRNA]; PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of NQO1 mRNA]]		 CTD PMID:21397656 PMID:33486071 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557 		JBrowse link
G Nsf N-ethylmaleimide sensitive factor, vesicle fusing ATPase decreases expression
multiple interactions		 EXP Oxidopamine results in decreased expression of NSF mRNA
isoquercitrin inhibits the reaction [Oxidopamine results in decreased expression of NSF mRNA]; Levodopa inhibits the reaction [Oxidopamine results in decreased expression of NSF mRNA]; Rutin inhibits the reaction [Oxidopamine results in decreased expression of NSF mRNA]		 CTD PMID:25129099 NCBI chr10:88,727,912...88,857,375
Ensembl chr10:88,727,912...88,857,386 		JBrowse link
G Nsg1 neuronal vesicle trafficking associated 1 decreases expression
multiple interactions		 EXP Oxidopamine results in decreased expression of NSG1 mRNA
isoquercitrin inhibits the reaction [Oxidopamine results in decreased expression of NSG1 mRNA]; Rutin inhibits the reaction [Oxidopamine results in decreased expression of NSG1 mRNA]		 CTD PMID:25129099 NCBI chr14:72,648,771...72,670,521
Ensembl chr14:72,648,741...72,670,514 		JBrowse link
G Oma1 OMA1 zinc metallopeptidase multiple interactions
increases expression		 EXP Emodin inhibits the reaction [Oxidopamine results in increased expression of OMA1 protein] CTD PMID:34971761 NCBI chr 5:118,083,728...118,136,980
Ensembl chr 5:118,083,728...118,136,980 		JBrowse link
G Opa1 OPA1, mitochondrial dynamin like GTPase multiple interactions
decreases expression		 EXP
ISO		 isoquercitrin inhibits the reaction [Oxidopamine results in decreased expression of OPA1 mRNA]; Levodopa inhibits the reaction [Oxidopamine results in decreased expression of OPA1 mRNA]; Rutin inhibits the reaction [Oxidopamine results in decreased expression of OPA1 mRNA]
Oxidopamine results in decreased expression of OPA1 protein
OPA1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; OPA1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]]; salvin inhibits the reaction [Oxidopamine results in decreased expression of OPA1 protein]		 CTD PMID:25129099 PMID:31705926 NCBI chr11:71,108,100...71,185,170
Ensembl chr11:71,109,873...71,185,109 		JBrowse link
G Oprl1 opioid related nociceptin receptor 1 decreases expression EXP Oxidopamine results in decreased expression of OPRL1 mRNA CTD PMID:19162046 NCBI chr 3:168,831,934...168,839,920
Ensembl chr 3:168,834,003...168,839,920 		JBrowse link
G P4hb prolyl 4-hydroxylase subunit beta increases expression EXP Oxidopamine results in increased expression of P4HB mRNA CTD PMID:12486162 NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500 		JBrowse link
G Park7 Parkinsonism associated deglycase multiple interactions
increases expression
decreases response to substance
affects localization		 ISO
EXP		 Oxidopamine promotes the reaction [Quinones binds to PARK7 protein]
Oxidopamine results in increased expression of PARK7 mRNA
[4-phenylbutyric acid results in increased expression of PARK7 protein] which results in decreased susceptibility to Oxidopamine; isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of PARK7 mRNA]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of PARK7 mRNA]; Rutin inhibits the reaction [Oxidopamine results in increased expression of PARK7 mRNA]
PARK7 protein results in decreased susceptibility to Oxidopamine
Oxidopamine results in increased expression of PARK7 mRNA; Oxidopamine results in increased expression of PARK7 protein
Oxidopamine affects the localization of PARK7 protein		 CTD PMID:18377993 PMID:20851755 PMID:21372141 PMID:25129099 NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage
increases activity
increases expression		 ISO
EXP		 OPA1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]]; pyrazolanthrone inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]; salvin inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]; TH protein inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]; tricetin inhibits the reaction [Oxidopamine results in increased expression of PARP1 protein]
5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato iron(III) chloride inhibits the reaction [Oxidopamine results in increased activity of PARP1 protein]; salvin inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]
2-chloro-5-hydroxyphenylglycine affects the reaction [Oxidopamine results in increased cleavage of PARP1 protein]; 6-methyl-2-(phenylethynyl)pyridine promotes the reaction [Oxidopamine results in increased cleavage of PARP1 protein]; GOPC protein affects the reaction [2-chloro-5-hydroxyphenylglycine affects the reaction [Oxidopamine results in increased cleavage of PARP1 protein]]; GOPC protein affects the reaction [6-methyl-2-(phenylethynyl)pyridine promotes the reaction [Oxidopamine results in increased cleavage of PARP1 protein]]; GOPC protein affects the reaction [Oxidopamine results in increased cleavage of PARP1 protein]		 CTD PMID:10397638 PMID:19815691 PMID:21397656 PMID:25446857 PMID:30707903 More... NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pdcd10 programmed cell death 10 multiple interactions EXP
ISO		 PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of HES1 protein]]; PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of NOTCH1 protein]]
[Oxidopamine affects the reaction [MIR107 mRNA binds to PDCD10 3' UTR]] which affects the expression of PDCD10 mRNA; [Oxidopamine affects the reaction [MIR107 mRNA binds to PDCD10 3' UTR]] which affects the expression of PDCD10 protein; Oxidopamine affects the reaction [MIR107 mRNA binds to PDCD10 3' UTR]; PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of HES1 protein]]; PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of NOTCH1 protein]]		 CTD PMID:31778666 NCBI chr 2:160,303,465...160,346,086
Ensembl chr 2:160,303,449...160,346,018 		JBrowse link
G Pdgfrb platelet derived growth factor receptor beta decreases expression EXP Oxidopamine results in decreased expression of PDGFRB mRNA CTD PMID:15518916 NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843 		JBrowse link
G Pdhb pyruvate dehydrogenase E1 subunit beta decreases expression ISO Oxidopamine results in decreased expression of PDHB mRNA CTD PMID:19763263 NCBI chr15:16,752,561...16,758,503
Ensembl chr15:16,750,980...16,758,500 		JBrowse link
G Pdia3 protein disulfide isomerase family A, member 3 increases expression EXP Oxidopamine results in increased expression of PDIA3 mRNA CTD PMID:12486162 NCBI chr 3:108,388,189...108,412,013
Ensembl chr 3:108,388,245...108,413,236 		JBrowse link
G Pdia6 protein disulfide isomerase family A, member 6 increases expression EXP Oxidopamine results in increased expression of PDIA6 mRNA CTD PMID:12486162 NCBI chr 6:40,062,980...40,080,223
Ensembl chr 6:40,062,926...40,080,613 		JBrowse link
G Pdyn prodynorphin multiple interactions
decreases expression
increases expression		 ISO
EXP		 [Levodopa co-treated with Oxidopamine] results in increased expression of PDYN mRNA; [Levodopa co-treated with Oxidopamine] results in increased expression of PDYN protein; Levodopa inhibits the reaction [Oxidopamine results in decreased expression of PDYN mRNA]
6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of PDYN mRNA]; [Levodopa co-treated with Oxidopamine] results in increased expression of PDYN mRNA; [Oxidopamine co-treated with Levodopa] results in increased expression of PDYN mRNA; [Oxidopamine co-treated with Levodopa] results in increased expression of PDYN protein; [TH co-treated with GCH1] inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of PDYN mRNA]; Corticosterone inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of PDYN mRNA]; IEM 1460 inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of PDYN mRNA]; Levodopa inhibits the reaction [Oxidopamine results in decreased expression of PDYN mRNA]
Oxidopamine results in increased expression of PDYN mRNA		 CTD PMID:7477882 PMID:12127155 PMID:14697317 PMID:15207268 PMID:15610165 More... NCBI chr 3:116,900,990...116,913,334
Ensembl chr 3:116,900,992...116,913,334 		JBrowse link
G Penk proenkephalin multiple interactions
increases expression		 ISO
EXP		 [Oxidopamine co-treated with Levodopa] results in increased expression of PENK mRNA
[Levodopa co-treated with Oxidopamine] results in increased expression of PENK mRNA; [Oxidopamine co-treated with Levodopa] results in increased expression of PENK mRNA; [TH co-treated with GCH1] inhibits the reaction [Levodopa promotes the reaction [Oxidopamine results in increased expression of PENK mRNA]]; Corticosterone inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of PENK mRNA]; IEM 1460 inhibits the reaction [Levodopa promotes the reaction [Oxidopamine results in increased expression of PENK mRNA]]; Isradipine inhibits the reaction [Oxidopamine results in increased expression of PENK mRNA]; Levodopa promotes the reaction [Oxidopamine results in increased expression of PENK mRNA]; S 33084 inhibits the reaction [[Levodopa co-treated with Oxidopamine] results in increased expression of PENK mRNA]
Oxidopamine results in increased expression of PENK mRNA; Oxidopamine results in increased expression of PENK protein		 CTD PMID:3838946 PMID:12127155 PMID:15065221 PMID:15659429 PMID:16139809 More... NCBI chr 5:17,183,799...17,189,160
Ensembl chr 5:17,183,806...17,189,129 		JBrowse link
G Pink1 PTEN induced kinase 1 decreases expression
multiple interactions		 ISO Oxidopamine results in decreased expression of PINK1 protein
PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of PRKN protein]]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of VDAC1 protein]]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]]; salvin inhibits the reaction [Oxidopamine results in decreased expression of PINK1 protein]		 CTD PMID:30707903 NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635 		JBrowse link
G Pnoc prepronociceptin increases expression
decreases expression		 EXP Oxidopamine results in increased expression of PNOC mRNA
Oxidopamine results in decreased expression of PNOC mRNA		 CTD PMID:19162046 NCBI chr15:39,624,635...39,652,463
Ensembl chr15:39,624,641...39,651,867 		JBrowse link
G Pomc proopiomelanocortin multiple interactions
increases expression		 EXP Levodopa promotes the reaction [Oxidopamine results in increased expression of POMC protein] CTD PMID:16325000 NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664 		JBrowse link
G Ppargc1a PPARG coactivator 1 alpha decreases expression
multiple interactions		 ISO Oxidopamine results in decreased expression of PPARGC1A protein
LY 344864 inhibits the reaction [Oxidopamine results in decreased expression of PPARGC1A protein]		 CTD PMID:29057453 NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656 		JBrowse link
G Ppib peptidylprolyl isomerase B increases expression EXP Oxidopamine results in increased expression of PPIB mRNA CTD PMID:12486162 NCBI chr 8:66,603,877...66,609,734
Ensembl chr 8:66,603,861...66,630,428 		JBrowse link
G Ppid peptidylprolyl isomerase D multiple interactions
increases expression		 EXP isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of PPID mRNA]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of PPID mRNA]; Rutin inhibits the reaction [Oxidopamine results in increased expression of PPID mRNA] CTD PMID:25129099 NCBI chr 2:164,727,803...164,740,168
Ensembl chr 2:164,727,779...164,740,221 		JBrowse link
G Ppp1r1b protein phosphatase 1, regulatory (inhibitor) subunit 1B multiple interactions ISO
EXP		 [benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of PPP1R1B protein
[Oxidopamine co-treated with Levodopa] affects the phosphorylation of PPP1R1B protein		 CTD PMID:17188499 PMID:17596448 NCBI chr10:83,347,731...83,356,775
Ensembl chr10:83,347,731...83,356,775 		JBrowse link
G Prkaca protein kinase cAMP-activated catalytic subunit alpha multiple interactions
decreases phosphorylation		 EXP Clenbuterol inhibits the reaction [Oxidopamine results in decreased phosphorylation of PRKACA protein]; Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of PRKACA protein]; Dobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of PRKACA protein] CTD PMID:16339297 NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430 		JBrowse link
G Prkcd protein kinase C, delta multiple interactions
increases response to substance		 ISO
EXP		 Oxidopamine results in increased cleavage of and results in increased activity of PRKCD protein
benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Oxidopamine results in increased cleavage of and results in increased activity of PRKCD protein]; Oxidopamine results in increased cleavage of and results in increased activity of PRKCD protein
PRKCD protein results in increased susceptibility to Oxidopamine		 CTD PMID:21846476 NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352 		JBrowse link
G Prkn parkin RBR E3 ubiquitin protein ligase decreases reaction
multiple interactions
increases expression
decreases expression
affects expression		 ISO
EXP		 PRKN protein inhibits the reaction Oxidopamine
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of PRKN mRNA]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of PRKN mRNA]; Rutin inhibits the reaction [Oxidopamine results in increased expression of PRKN mRNA]
PRKN protein inhibits the reaction [Oxidopamine results in decreased expression of TH protein]
PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of PRKN protein]]; salvin inhibits the reaction [Oxidopamine results in decreased expression of PRKN protein]; Tretinoin affects the reaction [Oxidopamine affects the expression of PRKN protein alternative form]		 CTD PMID:15198987 PMID:16914382 PMID:25129099 PMID:28688199 PMID:30707903 NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555 		JBrowse link
G Prss1 serine protease 1 multiple interactions
decreases activity		 EXP Resveratrol inhibits the reaction [Oxidopamine results in decreased activity of PRSS1 protein] CTD PMID:34302886 NCBI chr 4:70,364,589...70,367,792
Ensembl chr 4:70,364,586...70,367,792 		JBrowse link
G Psma2 proteasome 20S subunit alpha 2 increases expression EXP Oxidopamine results in increased expression of PSMA2 mRNA CTD PMID:12486162 NCBI chr17:50,554,536...50,564,923
Ensembl chr17:50,551,924...50,564,938 		JBrowse link
G Psmb2 proteasome 20S subunit beta 2 increases expression EXP Oxidopamine results in increased expression of PSMB2 mRNA CTD PMID:12486162 NCBI chr 5:138,970,564...139,002,715
Ensembl chr 5:138,970,533...139,021,137 		JBrowse link
G Psmc4 proteasome 26S subunit, ATPase 4 increases expression EXP Oxidopamine results in increased expression of PSMC4 mRNA CTD PMID:12486162 NCBI chr 1:83,349,127...83,357,497
Ensembl chr 1:83,348,592...83,357,494 		JBrowse link
G Ptger4 prostaglandin E receptor 4 increases expression ISO Oxidopamine results in increased expression of PTGER4 mRNA CTD PMID:31247335 NCBI chr 2:54,330,563...54,347,451
Ensembl chr 2:54,335,424...54,346,670 		JBrowse link
G Ptgfr prostaglandin F receptor increases expression
multiple interactions		 ISO Oxidopamine results in increased expression of PTGFR protein
PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of GCLM mRNA]]; PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of HMOX1 mRNA]]; PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of NQO1 mRNA]]; PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of TXNRD1 mRNA]]		 CTD PMID:33486071 NCBI chr 2:240,731,185...240,766,674
Ensembl chr 2:240,733,375...240,765,650 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions
increases expression		 ISO
EXP		 N-(4-O-glycerol-3-methoxybenzyl)nonivamide inhibits the reaction [Oxidopamine results in increased expression of PTGS2 protein]
Oxidopamine results in increased expression of PTGS2 mRNA; Oxidopamine results in increased expression of PTGS2 protein
rosiglitazone inhibits the reaction [Oxidopamine results in increased expression of PTGS2 protein]		 CTD PMID:17855475 PMID:20851755 PMID:22842585 PMID:31247335 PMID:33486071 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188 		JBrowse link
G Rasgrp1 RAS guanyl releasing protein 1 multiple interactions EXP [Levodopa co-treated with Oxidopamine] affects the expression of RASGRP1 mRNA; [Levodopa co-treated with Oxidopamine] affects the expression of RASGRP1 protein CTD PMID:19171906 NCBI chr 3:104,168,549...104,230,107
Ensembl chr 3:104,170,013...104,230,056 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions
affects localization
increases phosphorylation
increases activity		 EXP
ISO		 Oxidopamine results in increased localization of and results in increased activity of RELA protein; SN50 peptide inhibits the reaction [Oxidopamine results in increased localization of RELA protein]
N-(1-(4-(5-chloro-2-oxo-2,3-dihydro-1H-benzo(d)imidazol-1-yl)piperidin-1-yl)propan-2-yl)-2-naphthamide inhibits the reaction [Oxidopamine affects the localization of RELA protein]
chrysin inhibits the reaction [Oxidopamine results in increased phosphorylation of RELA protein]
Oxidopamine results in increased activity of RELA protein		 CTD PMID:17368433 PMID:20851755 PMID:29054324 PMID:31247335 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G Ret ret proto-oncogene decreases response to substance ISO RET protein mutant form results in decreased susceptibility to Oxidopamine CTD PMID:19767128 NCBI chr 4:151,325,969...151,368,176
Ensembl chr 4:151,326,431...151,368,176 		JBrowse link
G Rps6ka5 ribosomal protein S6 kinase A5 multiple interactions ISO [benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of RPS6KA5 protein; [Oxidopamine co-treated with Levodopa] results in increased expression of RPS6KA5 protein; SCH 23390 inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of RPS6KA5 protein]; SL 327 inhibits the reaction [[benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of RPS6KA5 protein] CTD PMID:17596448 PMID:19187092 NCBI chr 6:119,828,823...120,006,190
Ensembl chr 6:119,828,846...120,006,224 		JBrowse link
G S100b S100 calcium binding protein B multiple interactions
increases expression		 ISO chrysin inhibits the reaction [Oxidopamine results in increased expression of S100B protein] CTD PMID:29054324 NCBI chr20:12,372,866...12,381,619
Ensembl chr20:12,372,881...12,394,743 		JBrowse link
G Sec11c SEC11 homolog C, signal peptidase complex subunit increases expression EXP Oxidopamine results in increased expression of SEC11C mRNA CTD PMID:12486162 NCBI chr18:59,320,932...59,337,272
Ensembl chr18:59,320,884...59,337,364 		JBrowse link
G Serp1 stress-associated endoplasmic reticulum protein 1 increases expression EXP Oxidopamine results in increased expression of SERP1 mRNA CTD PMID:12486162 NCBI chr 2:142,757,254...142,761,243
Ensembl chr 2:142,757,270...142,761,116 		JBrowse link
G Sh3kbp1 SH3 domain-containing kinase-binding protein 1 increases expression ISO Oxidopamine results in increased expression of SH3KBP1 mRNA CTD PMID:18535749 NCBI chr  X:34,877,862...35,223,013
Ensembl chr  X:34,877,866...35,222,747 		JBrowse link
G Shh sonic hedgehog signaling molecule multiple interactions EXP SHH protein modified form affects the susceptibility to [Apomorphine co-treated with Oxidopamine]; SHH protein modified form affects the susceptibility to [Dextroamphetamine co-treated with Oxidopamine] CTD PMID:11771942 NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170 		JBrowse link
G Sirt1 sirtuin 1 multiple interactions
decreases expression		 ISO puag-haad inhibits the reaction [Oxidopamine results in decreased expression of SIRT1 protein] CTD PMID:18675900 NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260 		JBrowse link
G Slc18a2 solute carrier family 18 member A2 decreases expression
multiple interactions		 ISO
EXP		 Oxidopamine results in decreased expression of SLC18A2 mRNA
Oxidopamine results in decreased expression of SLC18A2 protein
Resveratrol inhibits the reaction [Oxidopamine results in decreased expression of SLC18A2 protein]		 CTD PMID:17803225 PMID:34302886 NCBI chr 1:258,413,748...258,449,143
Ensembl chr 1:258,413,959...258,448,325 		JBrowse link
G Slc1a2 solute carrier family 1 member 2 multiple interactions EXP [Levodopa co-treated with Oxidopamine] results in increased expression of SLC1A2 mRNA CTD PMID:17329435 NCBI chr 3:89,005,129...89,135,469
Ensembl chr 3:89,005,129...89,126,498 		JBrowse link
G Slc1a3 solute carrier family 1 member 3 increases expression EXP Oxidopamine results in increased expression of SLC1A3 mRNA CTD PMID:15518916 NCBI chr 2:57,755,495...57,830,605
Ensembl chr 2:57,755,497...57,830,605 		JBrowse link
G Slc40a1 solute carrier family 40 member 1 multiple interactions
decreases expression		 ISO
EXP		 Oxidopamine promotes the reaction [ACO1 protein results in decreased expression of SLC40A1 mRNA]; Oxidopamine promotes the reaction [IREB2 protein results in decreased expression of SLC40A1 mRNA]
Oxidopamine results in decreased expression of SLC40A1 mRNA; Oxidopamine results in decreased expression of SLC40A1 protein		 CTD PMID:19913091 NCBI chr 9:48,033,526...48,053,876
Ensembl chr 9:48,033,526...48,051,481 		JBrowse link
G Slc6a3 solute carrier family 6 member 3 decreases expression
increases response to substance
increases expression
multiple interactions		 EXP
ISO		 Oxidopamine results in decreased expression of SLC6A3 mRNA; Oxidopamine results in decreased expression of SLC6A3 protein
SLC6A3 protein results in increased susceptibility to Oxidopamine
Oxidopamine results in increased expression of SLC6A3 mRNA; Oxidopamine results in increased expression of SLC6A3 protein
Resveratrol inhibits the reaction [Oxidopamine results in increased expression of SLC6A3 protein]		 CTD PMID:10881039 PMID:15303306 PMID:15518916 PMID:20200117 PMID:34252731 More... NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413 		JBrowse link
G Slc6a4 solute carrier family 6 member 4 multiple interactions EXP [Oxidopamine co-treated with Levodopa] results in increased expression of SLC6A4 protein CTD PMID:20882603 NCBI chr10:61,824,208...61,858,924
Ensembl chr10:61,826,123...61,858,384 		JBrowse link
G Snai3 snail family transcriptional repressor 3 increases expression ISO Oxidopamine results in increased expression of SNAI3 mRNA CTD PMID:32870474 NCBI chr19:50,516,771...50,529,295
Ensembl chr19:50,516,771...50,523,486 		JBrowse link
G Snca synuclein alpha increases expression
increases response to substance		 ISO
EXP		 Oxidopamine results in increased expression of SNCA mRNA alternative form
SNCA protein mutant form results in increased susceptibility to Oxidopamine
Oxidopamine results in increased expression of SNCA protein		 CTD PMID:16297908 PMID:19857570 PMID:22016808 PMID:31022188 NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262 		JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions
decreases expression		 ISO
EXP		 salvin inhibits the reaction [Oxidopamine results in decreased expression of SOD1 protein]
Oxidopamine results in decreased expression of SOD1 mRNA; Oxidopamine results in decreased expression of SOD1 protein		 CTD PMID:11730701 PMID:25446857 NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249 		JBrowse link
G Sod2 superoxide dismutase 2 affects expression EXP Oxidopamine affects the expression of SOD2 mRNA CTD PMID:11730701 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189 		JBrowse link
G Spp1 secreted phosphoprotein 1 decreases expression EXP Oxidopamine results in decreased expression of SPP1 protein CTD PMID:24486959 NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162 		JBrowse link
G Sqstm1 sequestosome 1 multiple interactions
decreases expression		 ISO
EXP		 Oxidopamine promotes the reaction [SQSTM1 protein binds to and results in decreased activity of SQSTM1 protein]
Oxidopamine results in decreased expression of SQSTM1 protein		 CTD PMID:26409479 PMID:28802652 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
G Ssr2 signal sequence receptor subunit 2 increases expression EXP Oxidopamine results in increased expression of SSR2 mRNA CTD PMID:12486162 NCBI chr 2:174,048,291...174,057,043
Ensembl chr 2:174,048,460...174,057,042 		JBrowse link
G Ssr4 signal sequence receptor subunit 4 increases expression EXP Oxidopamine results in increased expression of SSR4 mRNA CTD PMID:12486162 NCBI chr  X:151,524,191...151,528,218
Ensembl chr  X:151,524,009...151,528,202 		JBrowse link
G Stub1 STIP1 homology and U-box containing protein 1 multiple interactions
increases expression		 EXP isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of STUB1 mRNA]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of STUB1 mRNA] CTD PMID:25129099 NCBI chr10:14,850,765...14,853,046
Ensembl chr10:14,850,765...14,853,046 		JBrowse link
G Syp synaptophysin multiple interactions
decreases expression		 EXP Resveratrol inhibits the reaction [Oxidopamine results in decreased expression of SYP protein] CTD PMID:34302886 NCBI chr  X:14,849,444...14,864,553
Ensembl chr  X:14,849,444...14,864,745 		JBrowse link
G Tac1 tachykinin, precursor 1 decreases expression
increases expression		 EXP Oxidopamine results in decreased expression of TAC1 mRNA
Oxidopamine results in increased expression of TAC1 mRNA		 CTD PMID:15303306 PMID:15610165 PMID:18687386 NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178 		JBrowse link
G Tfam transcription factor A, mitochondrial multiple interactions
decreases expression		 ISO LY 344864 inhibits the reaction [Oxidopamine results in decreased expression of TFAM protein] CTD PMID:29057453 NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292 		JBrowse link
G Tfeb transcription factor EB multiple interactions ISO [Oxidopamine co-treated with Celecoxib] results in increased expression of TFEB mRNA; Oxidopamine promotes the reaction [Celecoxib results in increased expression of TFEB mRNA] CTD PMID:33160981 NCBI chr 9:13,198,890...13,254,726
Ensembl chr 9:13,198,891...13,254,714 		JBrowse link
G Th tyrosine hydroxylase affects response to substance
multiple interactions
decreases expression		 ISO
EXP		 TH protein affects the susceptibility to Oxidopamine
TH protein inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]
Oxidopamine results in decreased expression of TH mRNA; Oxidopamine results in decreased expression of TH protein
LY 344864 inhibits the reaction [Oxidopamine results in decreased expression of TH protein]; PRKN protein inhibits the reaction [Oxidopamine results in decreased expression of TH protein]; sulforaphane inhibits the reaction [Oxidopamine results in decreased expression of TH protein]
2-chloro-5-hydroxyphenylglycine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the expression of TH protein]; 3-methyladenine inhibits the reaction [Oxidopamine results in decreased expression of TH protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the expression of TH protein]; [GOPC protein affects the susceptibility to Oxidopamine] which affects the expression of TH protein; [TH co-treated with GCH1] inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of FOSB protein]; [TH co-treated with GCH1] inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of PDYN mRNA]; [TH co-treated with GCH1] inhibits the reaction [Levodopa promotes the reaction [Oxidopamine results in increased expression of PENK mRNA]]; Drugs, Chinese Herbal inhibits the reaction [Levodopa promotes the reaction [Oxidopamine results in decreased expression of TH mRNA]]; isoquercitrin promotes the reaction [Oxidopamine results in decreased expression of TH mRNA]; Levodopa inhibits the reaction [Oxidopamine results in decreased expression of TH mRNA]; Levodopa promotes the reaction [Oxidopamine results in decreased expression of TH mRNA]; MDL 201053 inhibits the reaction [Oxidopamine results in decreased expression of TH protein]; Resveratrol inhibits the reaction [Oxidopamine results in decreased expression of TH protein]; Rosiglitazone inhibits the reaction [Oxidopamine results in decreased expression of TH protein]; Rutin inhibits the reaction [Oxidopamine results in decreased expression of TH mRNA]; salvin inhibits the reaction [Oxidopamine results in decreased expression of TH protein]; Tea inhibits the reaction [Oxidopamine results in decreased expression of TH mRNA]; Tea inhibits the reaction [Oxidopamine results in decreased expression of TH protein]		 CTD PMID:9460767 PMID:11730701 PMID:12585172 PMID:14696016 PMID:15659429 More... NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767 		JBrowse link
G Timp2 TIMP metallopeptidase inhibitor 2 decreases expression
decreases response to substance		 ISO Oxidopamine results in decreased expression of TIMP2 mRNA; Oxidopamine results in decreased expression of TIMP2 protein
TIMP2 protein results in decreased susceptibility to Oxidopamine		 CTD PMID:19883732 NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611 		JBrowse link
G Tnf tumor necrosis factor increases expression
multiple interactions		 EXP
ISO		 Oxidopamine results in increased expression of TNF protein
Resveratrol inhibits the reaction [Oxidopamine results in increased expression of TNF protein]; Rosiglitazone inhibits the reaction [Oxidopamine results in increased expression of TNF protein]
chrysin inhibits the reaction [Oxidopamine results in increased expression of TNF protein]		 CTD PMID:22842585 PMID:29054324 PMID:34302886 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Tnfrsf1b TNF receptor superfamily member 1B decreases response to substance ISO TNFRSF1B protein results in decreased susceptibility to Oxidopamine CTD PMID:22110694 NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206 		JBrowse link
G Tor1a torsin family 1, member A decreases expression EXP Oxidopamine results in decreased expression of TOR1A protein CTD PMID:16325337 NCBI chr 3:14,250,667...14,257,704
Ensembl chr 3:14,250,676...14,257,691 		JBrowse link
G Tp53 tumor protein p53 multiple interactions
increases expression		 EXP SN50 peptide inhibits the reaction [Oxidopamine results in increased expression of TP53 protein] CTD PMID:17368433 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524 		JBrowse link
G Trh thyrotropin releasing hormone multiple interactions EXP [Levodopa co-treated with Oxidopamine] results in increased expression of TRH mRNA; [Levodopa co-treated with Oxidopamine] results in increased expression of TRH protein CTD PMID:21085660 NCBI chr 4:124,742,111...124,777,094
Ensembl chr 4:124,742,111...124,744,637 		JBrowse link
G Txnrd1 thioredoxin reductase 1 multiple interactions
increases expression		 ISO fluprostenol promotes the reaction [Oxidopamine results in increased expression of TXNRD1 mRNA]; PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of TXNRD1 mRNA]] CTD PMID:33486071 NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863 		JBrowse link
G Ubc ubiquitin C increases expression EXP Oxidopamine results in increased expression of UBC mRNA CTD PMID:12486162 NCBI chr12:31,239,149...31,243,924
Ensembl chr12:31,239,152...31,243,925 		JBrowse link
G Ube2d3 ubiquitin-conjugating enzyme E2D 3 increases expression EXP Oxidopamine results in increased expression of UBE2D3 mRNA CTD PMID:12486162 NCBI chr 2:223,868,397...223,899,606
Ensembl chr 2:223,868,730...223,898,081 		JBrowse link
G Uchl1 ubiquitin C-terminal hydrolase L1 multiple interactions
increases expression		 EXP isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of UCHL1 mRNA]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of UCHL1 mRNA]; Rutin inhibits the reaction [Oxidopamine results in increased expression of UCHL1 mRNA] CTD PMID:25129099 NCBI chr14:41,485,031...41,495,590
Ensembl chr14:41,485,031...41,495,590 		JBrowse link
G Vdac1 voltage-dependent anion channel 1 multiple interactions ISO Oxidopamine results in decreased expression of and results in decreased ubiquitination of VDAC1 protein; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of VDAC1 protein]]; salvin inhibits the reaction [Oxidopamine results in decreased expression of and results in decreased ubiquitination of VDAC1 protein] CTD PMID:30707903 NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19808
    role 19784
      biological role 19782
        molecular messenger 18611
          monoamine molecular messenger 611
            catecholamine 557
              dopamine 378
                (2E)-N-[2-(3,4-dihydroxyphenyl)ethyl]-3-(3,4-dimethoxyphenyl)acrylamide 0
                15-HETE-DA 0
                3-amino-N-[2-(3,4-dihydroxyphenyl)ethyl]propanamide 0
                3-methoxytyramine + 2
                4-methoxytyramine 1
                Arachidonoyl dopamine 0
                Dihomo-gamma-linolenoyl dopamine 0
                N-[2-(3,4-dihydroxyphenyl)ethyl]-9-octadecenamide 0
                N-[2-(3,4-dihydroxyphenyl)ethyl]-L-glutamine residue 0
                N-acetyldopamine 1
                N-linoleoyl dopamine 0
                N-oleoyldopamine 4
                N-palmitoyl dopamine 2
                N-stearoyl dopamine 0
                dopamine 3-O-sulfate 0
                dopamine 4-O-sulfate 0
                oxidopamine 200
Path 2
Term Annotations click to browse term
  CHEBI ontology 19808
    subatomic particle 19806
      composite particle 19806
        hadron 19806
          baryon 19806
            nucleon 19806
              atomic nucleus 19806
                atom 19806
                  main group element atom 19756
                    main group molecular entity 19756
                      s-block molecular entity 19595
                        hydrogen molecular entity 19582
                          hydrides 19095
                            inorganic hydride 18093
                              pnictogen hydride 18082
                                nitrogen hydride 17989
                                  azane 17798
                                    ammonia 17797
                                      organic amino compound 17797
                                        aralkylamino compound 1008
                                          monoamine 611
                                            monoamine molecular messenger 611
                                              catecholamine 557
                                                dopamine 378
                                                  (2E)-N-[2-(3,4-dihydroxyphenyl)ethyl]-3-(3,4-dimethoxyphenyl)acrylamide 0
                                                  15-HETE-DA 0
                                                  3-amino-N-[2-(3,4-dihydroxyphenyl)ethyl]propanamide 0
                                                  3-methoxytyramine + 2
                                                  4-methoxytyramine 1
                                                  Arachidonoyl dopamine 0
                                                  Dihomo-gamma-linolenoyl dopamine 0
                                                  N-[2-(3,4-dihydroxyphenyl)ethyl]-9-octadecenamide 0
                                                  N-[2-(3,4-dihydroxyphenyl)ethyl]-L-glutamine residue 0
                                                  N-acetyldopamine 1
                                                  N-linoleoyl dopamine 0
                                                  N-oleoyldopamine 4
                                                  N-palmitoyl dopamine 2
                                                  N-stearoyl dopamine 0
                                                  dopamine 3-O-sulfate 0
                                                  dopamine 4-O-sulfate 0
                                                  oxidopamine 200
paths to the root